Applying a Mother-Infant Dyad Perspective to Examine the Nutritional Interrelationships of HIV-Infected Malawian Mothers and Their Exclusively Breastfed Infants by Widen, Elizabeth Marie
  
 
 
 
 
 
APPLYING A MOTHER-INFANT DYAD PERSPECTIVE TO EXAMINE THE 
NUTRITIONAL INTERRELATIONSHIPS OF HIV-INFECTED MALAWIAN 
MOTHERS AND THEIR EXCLUSIVELY BREASTFED INFANTS 
 
 
 
 
 
Elizabeth Marie Widen 
 
 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill 
in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Department of Nutrition, Gillings School of Global Public Health. 
 
 
 
 
 
Chapel Hill 
2012 
 
 
 
Approved by: 
Dr. Linda S. Adair 
Dr. Margaret E. Bentley 
Dr. Michael Hudgens 
Dr. Charles van der Horst 
Dr. Anna-Maria Siega-Riz 
Dr. Catherine Zimmer 
  ii
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2012 
Elizabeth Marie Widen 
ALL RIGHTS RESERVED 
  
  iii 
 
 
 
Abstract 
ELIZABETH MARIE WIDEN: Applying a mother-infant dyad perspective to examine 
the nutritional interrelationships of HIV-infected Malawian women and their exclusively 
breastfed infants  
(Under the direction of Linda Adair) 
 
 
We used data from a large clinical trial, the Breastfeeding, Antiretrovirals and 
Nutrition (BAN) Study (www.thebanstudy.org), and a nutrition sub-study of BAN, the 
Malawi Mothers and Infants (MaMi) Study. The BAN study was a large clinical trial that 
aimed to promote maternal and infant health in HIV-infected Malawian women and their 
infants, and to prevent maternal to child transmission of HIV by providing a lipid based 
nutrient supplement (LNS) to the mother and antiretroviral drugs to the mother or infant. 
Mother-infant pairs (n=2,369) were randomized using a two-arm nutritional and three-
arm drug to six study arms: maternal LNS/maternal ARV (mLNS-mARV), maternal 
LNS/infant ARV (mLNS-iARV), maternal LNS (mLNS), maternal ARV (mARV), infant 
ARV (iARV), or control (C). The data used in this analysis was derived from screening 
visits and numerous visits from birth to 24 weeks postpartum. This study provided a 
novel opportunity to understand how maternal nutritional status was related to infant 
status, and how infant status related to maternal status. We chose to examine two 
important aspects of maternal and infant nutritional status during this time: iron and 
anthropometry. We observed that among mothers with low body mass index (BMI) 
maternal weight loss was related to less infant weight and length gain from birth to six 
months in girls. In longitudinal models, higher maternal Hb was associated with higher 
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concurrently measured infant Hb, especially between 6 and 18 wk. In the MaMi 
substudy, we observed that increases in maternal TfR and Hb were associated with an 
increase in infant Hb and TfR from initial measurement to 24 weeks. These findings 
suggest that maternal breastmilk quality may be compromised in thin women who lose 
weight, adversely affecting infant growth in females. The observed maternal influence in 
iron models suggests optimizing maternal iron status during pregnancy and lactation is 
important for reducing risk of infant iron depletion. Together these results highlight that 
promoting maternal nutritional status benefits not only the mother, but her infant as well.   
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Chapter 1.  Introduction 
Overview 
The mother is the sole source of nutrition for the infant during exclusive 
breastfeeding, yet there is little known about how maternal and infant nutritional statuses are 
interrelated and interdependent throughout this time. Though maternal health and nutritional 
status are important determinants of breastmilk quality and quantity, maternal nutritional 
status during lactation has primarily been examined as a predictor of child nutritional 
outcomes; rarely have the effects of infant nutritional status on maternal nutritional status 
been explored. As we are interested in the health and nutritional status of the mother-infant 
dyad, we framed our analyses to explore the interrelationships between maternal and child 
nutrition statuses, to understand the balance between infant nutrient demand and maternal 
nutritional supply during lactation, and to determine how this relates to infant and maternal 
anthropometry and iron status. 
We developed novel methods to explore the intricate interplay and dynamics between 
the mother and infant during this time period. In resource poor settings with high HIV 
prevalence, these relationships may be especially important for long-term maternal and child 
survival, health, and nutritional status. There currently is a dearth of literature on the 
nutritional statuses of HIV-infected mothers and their HIV-exposed infants during 
breastfeeding. These mothers may be unable to simultaneously meet their own and their 
infant’s nutritional needs which could adversely affect the long term health of the mother-
infant dyad and may increase susceptibility to pathogens and mother to child transmission of 
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HIV. Therefore our research provides urgently needed evidence regarding how maternal and 
infant nutritional statues are interrelated and interdependent between HIV-infected women 
and their infants in resource poor settings.  
Overall objectives and specific aims. 
  This study focused on the relationships between maternal and infant nutritional status 
in HIV-infected lactating women and their exclusively breastfed HIV-exposed, uninfected 
(HIV-EU) infants. We used data from the Breastfeeding, Antiretrovirals and Nutrition Study 
(BAN), a randomized controlled trial of 2,369 Malawian HIV infected women and their 
infants to prevent HIV transmission during exclusive breastfeeding conducted between 
March 2004 and January 2010 in Lilongwe, Malawi, as well as a sub-study of BAN, the 
Malawi Mothers and Infants Study (MaMi).1 BAN is unique as it has parallel longitudinal 
maternal and infant measures of nutritional status, including anthropometry and 
micronutrient status, during exclusive breastfeeding. We focused on the HIV exposed, 
uninfected infants and their mothers in BAN, who were followed during pregnancy, birth and 
1, 2, 4, 6, 8, 12, 18, 21 and 24 weeks postpartum.1 The overall goal of this study was to 
determine the interrelationships of maternal and infant nutrition status during exclusive 
breastfeeding. Specific aims for this study are as follows: 
Aim 1: Determine the interrelationships between maternal and infant anthropometry 
during exclusive breastfeeding in HIV-infected mothers and their infants.  
First, we developed models to determine how maternal weight loss between 2 and 24 weeks 
postpartum influenced infant growth. We hypothesized that infants of mothers losing weight 
during lactation will have suboptimal growth.  
Aim 2: Determine how maternal iron status during lactation influences infant iron 
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status during exclusive breastfeeding in HIV-infected mothers and their infants.  
First, we developed longitudinal models to determine how maternal hemoglobin (Hb) was 
associated with concurrently measured infant Hb from 2 to 24 weeks. Then we developed 
models to determine the association between maternal and infant transferrin receptors (TfR), 
Ferritin and Hb at 2 and 24 weeks postpartum in the MaMi subsample of mother-infant pairs 
after accounting for inflammation and infection. We hypothesized that infant Hb at birth and 
maternal Hb during lactation will influence infant Hb longitudinally, and that effects of 
maternal Hb will be more marked approaching the 24th week of exclusive breastfeeding when 
infant iron stores are more likely to be depleted. We also hypothesized that maternal Hb, TfR 
and Ferritin will predict infant values in the MaMi sub-sample of mother-infant pairs.
  
 
 
 
Chapter 2. Literature Review 
 
The mother infant dyad 
  The mother-infant dyad is a conceptual construct to define the connections between 
the mother and her infant. Previous research examining the mother-infant dyad has focused 
particularly on mother-infant interactions and attachment during breastfeeding and infancy.2,3 
The dyad has also been studied with regard to evolutionary adaptations to the composition of 
breast milk.4,5 Numerous authors have indicated that breastmilk production is focused not 
only on the survival of the infant, but also on the survival of the mother-infant dyad;4 
suggesting that “maximum evolutionary gain is obtained when protein and energy levels in 
breastmilk are just high enough to prevent prohibitive infant mortality rates, but low enough 
to spare the mother.”5 Although we did not test this hypothesis, it provided a framework for 
our analyses, as we included the health and nutritional status of the mother as a critical 
component of breastfeeding as well as infant health and survival.   
Why anthropometry and iron? 
These are two major markers of maternal and child health and nutritional status. 
Maternal and infant anthropometry measures reflect short and long-term energy balance and 
overall body composition; providing a general understanding of overall nutritional status, 
which can easily be translated to public health recommendations. As HIV-infected women 
have increased energy needs, determining if and when maternal anthropometry changes 
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influence infant anthropometry and conversely if and when infant growth influences maternal 
anthropometry is even more important in the context of HIV.  
   As iron deficiency is a major public health problem affecting 42% of pregnant 
women and almost half of preschool aged children globally,6 it is vital to understand if and 
when maternal and infant iron statuses are related during exclusive breastfeeding. In the 
context of HIV, iron deficiency is common among HIV-infected women; as such their infants 
are at heightened risk of iron deficiency. Elucidating this relationship is essential as iron is 
critical for growth, brain development and immune function.7 Both iron status and 
anthropometry are commonly measured in public health settings; therefore, our findings can 
be translated into public health screening and interventions that can be broadly implemented. 
Methods to evaluate the maternal supply and infant demand relationships have not 
been developed 
 
  The relationship between maternal weight changes and infant growth is complicated 
by the feedback loop between infant breastmilk demand and maternal breastmilk supply 
(Figure 2.1). When infant demand increases, maternal breastmilk production will increase, 
subsequently affecting maternal nutritional status. With insufficient dietary intake to meet the 
energy costs of lactation and also due to hormonal influences, maternal fat stores may be 
mobilized, and weight changes may result.8 Increased infant milk intake will subsequently 
influence infant growth and may lead to additional increases in infant demand and added 
burden on maternal nutritional status, as a rapidly growing infant is likely to demand more 
milk.8 Given adequate nutrient stores and dietary intake, most women may be able to meet 
infant breastmilk demand; however, if the mother is undernourished, and has inadequate 
dietary intake or energy reserves, breastmilk energy output may decrease,9 adversely 
affecting infant growth. Meeting infant demand may be particularly challenging for HIV 
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infected mothers, as energy needs are already elevated due to HIV infection; thus examining 
how maternal supply relates to infant demand is even more imperative in the context of HIV.   
 
Figure 2.1 Maternal supply and infant demand 
The dashed arrows indicate where infant demand may exert influence on maternal nutritional 
status.Image adapted from “Influence of maternal nutrition on lactation” by Kathy 
Rasmussen.8 
 
    Previous analyses utilizing a supply-demand model have tested the fetal origins 
hypothesis by examining how nutrient restriction during pregnancy relates to markers of 
cardiovascular disease risk.10,11 Because these prior analyses focused only on maternal 
exposures during pregnancy, feedback loops did not complicate these analyses. Accounting 
for maternal supply and infant demand when evaluating nutritional status during exclusive 
breastfeeding is complex, as feedback loops cannot be incorporated into linear models. To 
overcome the constraints of standard regression models, modeling approaches that allow for 
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incorporation of feedback loops and for testing of complex causal relationships are urgently 
needed; but difficult to implement.  
Maternal anthropometry patterns are highly variable during lactation and are not well 
understood in the context of HIV  
 
  During the first six months postpartum, most lactating women experience mild and 
gradual weight loss.12 Among well-nourished women, breastfeeding is usually associated 
with earlier return to pre-pregnancy weight.13,14 Among undernourished women, though, 
weight loss, weight maintenance and even moderate weight gain have been reported.15-18 
Anthropometry patterns during lactation have been less well described in HIV infected 
women. Similar to HIV uninfected women, though, the findings are inconsistent with studies 
reporting both gains and losses during lactation.13 
Maternal nutritional status and lactation performance 
  Studies have shown that breastfeeding can deplete energy and nutrient reserves of 
women with inadequate dietary intake and poor maternal nutrition can influence breastmilk 
quantity and nutrient quality.8,18,19 Brown et al (1986) examined the lactational capacity of 
marginally nourished mothers of Bangladeshi infants by examining relationships between 
maternal nutritional status and breastmilk quantity and quality.20 In mothers (n=60) with 
infants who were 90 days old, an association was found between the change in maternal 
weight from baseline and the quantity of milk, as well as nitrogen and energy content of 
milk.20 Furthermore, women who gained at least 200 grams from baseline produced more 
breastmilk with higher amounts of nitrogen and energy regardless of initial maternal 
weight.20 On the contrary, increasing maternal arm circumference was negatively associated 
with quantity of milk produced; yet this was speculated to result from multicollinearity 
between maternal arm circumference and weight (R=0.70).20 Furthermore, poor maternal 
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nutritional status did not severely impair lactational capacity; though, it limited breastmilk 
quantity and energy concentration compared to more well nourished mothers.20 
  How maternal HIV infection influences breastmilk supply and lactation performance 
is not well documented.  Prior studies regarding lactation of HIV infected women have 
focused on issues related to HIV transmission including breastmilk viral load and 
micronutrient content after heat treatment,21,22 rather than the relation of maternal nutritional 
status to the nutrient content and quantity of breastmilk.  
Anthropometry patterns of infants during exclusive breastfeeding 
  After birth infants typically lose weight in the first few days of life, and then return to 
birth weight by the seventh to tenth day of life.23 Subsequent growth proceeds at a “rapid but 
decelerating rate.”23 Birthweight is usually doubled by four to six months of age, and tripled 
by one year of age.23 Among well-nourished infants, length is increased by 50% in the first 
year, and is doubled by four years of age.23  
  It is well established that anthropometry patterns of healthy breastfed infants are 
different than artificially fed infants.24 Moreover, the growth patterns of breastfed HIV 
exposed infants are similar to HIV unexposed infants.25 In less developed countries, most 
studies have indicated a lack of association between HIV exposure and postnatal growth 
parameters including length-for-age, weight-for-age, and weight-for-length compared to HIV 
unexposed infants.25 Though there are some studies of the growth patterns of HIV-EU, most 
of these studies had limited numbers of HIV exposed children and had few anthropometry 
measurements from birth to 6 months.25 More evidence is needed to understand infant growth 
patterns and predictors in HIV exposed infants during this time period.  
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Few studies have examined how maternal weight changes translate into infant weight 
and length gain with a longitudinal design 
 
  In the East Java Pregnancy Study, increasing maternal post-partum body mass index 
(BMI) (kg/m2), measured between 4-6 months, was associated with higher infant weight and 
length gains between birth and 6 months.26 Interestingly, infants with lower birthweight had 
higher length and weight gains compared to infants with higher birthweight; indicating that 
the breastmilk quality and quantity was sufficient to promote growth of smaller infants, but 
the growth of infants with higher nutritional needs was compromised.26 Most of the infants in 
another study in this population were partially breastfed starting within the first month of life; 
thus partial breastfeeding (and subsequent exposure to pathogens and other foods) may have 
biased the effect of post-partum BMI on weight and length gain in this analysis.26 In Bolivian 
mother-infant pairs, weight and height at 3 months postpartum were positively correlated 
with infant weight gain between 3 and 6 months.27 These findings suggest associations 
between maternal and infant anthropometry; however, maternal body composition during 
early lactation and potential confounding variables such as maternal education, parity and 
morbidity were not accounted for in the models. Moreover, as exclusive breastfeeding may 
not have continued through the duration of these prior studies, the mother may no longer be 
the sole source of nutrition for her infant; thus effect estimates may be biased.  
The effects of maternal supplementation on infant growth 
  Several studies have examined the effects of maternal supplementation during 
pregnancy and lactation on infant growth including Institute of Nutrition of Central America 
and Panama Oriente longitudinal study in Guatemala and The Bacon Chow Study in Taiwan. 
In the Oriente longitudinal study conducted between 1969 and 1977, the effects of maternal 
supplementation during pregnancy and lactation on infant growth were examined.28 Mothers 
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were supplemented with a protein-calorie supplement (‘atole’, gruel typically made with 
corn) or caloric supplement (‘fresco’, cool drink).28 Though not significant, maternal 
supplementation had a positive effect (0.05 < p < 0.10) on infant weight gain from birth to 6 
months.28 Moreover, infants were also supplemented with atole or fresco, thus the effect of 
maternal supplementation on infant growth cannot be isolated from the effect of infant 
supplementation.28 Infant supplementation before 3 months had negative effects on infant 
weight gain (p<0.001), whereas infant supplementation between 3 and 6 months of age was 
found to positively influence infant growth (p<0.01).28 In the Bacon Chow Study conducted 
in rural Taiwan starting in 1967 for 6.5 years, the effect of maternal supplementation on 
infant growth was examined in mothers who gave birth to two infants during course of the 
study.29 Mothers were randomized to supplementation with a milk-based formula, providing 
800 calories and 40 grams of protein per day, or a placebo, providing 40 calories per day, 
starting at 15 days after the birth of the first infant and continuing through weaning of the 
second infant.29 There were no significant differences between maternal supplementation 
versus placebo; whereas the timing of maternal supplementation was important, yet 
inconsistent.29 Boys were heavier in the second infant cohort (p=0.02) compared to the first 
cohort.29 Conversely, girls were heavier in the first infant cohort (p=0.05) compared to the 
second.29   
  In the context of HIV, few maternal supplementation studies have been conducted 
that examine its effect on infant growth. One study in Tanzania found that micronutrient 
supplementation during and after pregnancy improved child growth.30 Another study in 
Tanzania focused on micronutrient supplementation during pregnancy, finding a decreased 
risk of intrauterine growth restriction with supplementation.31 Previously we observed that 
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maternal supplementation with lipid base nutrient supplement (LNS) in BAN participants 
had no sustained or consistent effects on infant growth from birth to 24 weeks.32 
By extending our analyses from anthropometry to iron status, we will explore the 
mother-infant nutritional dyad in two domains 
 
  Maternal iron status may influence infant iron status during exclusive breastfeeding; 
however, many additional factors influence infant iron needs and status. Infant iron stores at 
birth reflect maternal pregravid and pregnancy iron status, gestational age and birthweight of 
the infant, and timing of cord clamping.33 Many factors influence post-natal infant iron status 
including redistribution of body iron, growth rate, infections and inflammation, and possibly 
breastmilk iron status.33 Postnatally, infant Hb exhibits dynamic changes with a peak at birth 
of approximately 17 g/dL and a nadir of 11.2 g/dL at 2 months of age.33 Few studies have 
characterized the iron status of exclusively breastfed HIV-exposed infants.34 
  Most literature suggests maternal iron status strongly affects infant iron status only 
during pregnancy and has little effect during lactation;33,35 however, we theorize that in our 
population of HIV-infected Malawian women, whose iron stores are likely depleted 
postpartum, maternal iron status may be an important determinant of infant iron status during 
exclusive breastfeeding. Further investigation of this association is essential, particularly in 
women who are already at risk of anemia, such as our population of HIV infected women, as 
their infants may be at heightened risk of iron deficiency.36,37  
Why Malawi? 
  Malawi provides a unique opportunity to study the interrelations of maternal and 
infant nutritional status in a resource poor setting in the context of HIV. When the BAN 
study began in 2004, almost all Malawian infants were breastfed for some time, with a 
median duration of breastfeeding of 23.2 months.38 The median duration of exclusive 
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breastfeeding was 2.5 months, while the median duration of predominant breastfeeding was 
4.8 months.38 Though the WHO recommends six months of exclusive breastfeeding, 37% of 
infants ages 4-5 months were given complementary foods.38 
  Based on the most recent Demographic and Health Survey Data, HIV prevalence in 
Malawi among women of child bearing age is 12% with about a quarter of new infections 
due to mother to child transmission.38 Similar to other resource poor settings, food security in 
Malawi exhibits seasonal variation, with lowest food supplies in rainy season and highest 
supplies during harvest season.39 Given the poor food environment and staple foods of low 
nutritional value, maternal and child nutritional status in Malawi is poor. Among children 
under 5 years of age, stunting prevalence is very high (48%), while about a quarter of 
children are underweight.38,40 As almost half of women of childbearing age have iron 
deficiency anemia, it is not surprising that almost 80% of preschool aged children have iron 
deficiency anemia.38 As maternal and child nutrition in Malawi is suboptimal, our findings 
provide direly needed evidence for interventions and policies targeting the mother-infant 
dyad and, furthermore, bring the health and nutritional status of mothers into focus.  
  Several formative studies for BAN were conducted regarding infant feeding and 
maternal nutrition, providing contextual background for our research. Attitudes of the role of 
maternal nutrition in breastfeeding among HIV positive women was examined through in-
depth interviews with twenty-two HIV positive women living in semirural areas near 
Lilongwe.41 Most of the women perceived that larger body shapes were healthier and were 
aware of the need to maintain a high-quality diet for their own health and to meet the 
nutritional demands of lactation.41 Additional formative research for BAN investigated 
attitudes regarding infant feeding practices.42 Semi-structured interviews were conducted 
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with 40 HIV positive mothers. 85% of HIV positive mothers reported giving water or 
porridge to their infant before 4 months of age.42 Moreover, 60% of the 17 mothers with 
undisclosed HIV status had introduced complementary foods before 6 months of age.42 One 
mother reported: “Traditionally, we are told that if a child cries it is a sign of hunger. 
Because my baby was crying, I thought my breast milk was not adequate, so I started giving 
him water at 3 months.”42 These formative studies guided the development of the infant-
feeding counseling protocol for BAN.43 The implementation of the BAN infant-feeding 
counseling protocol was evaluated with observations of counseling sessions and interviews 
with the study nurses in a convenience sample of 123 HIV positive mothers who visited the 
study clinic between November and December 2005.43  Through process evaluation of the 
nurses’ adherence to the protocol indicate an average adherence to the protocol of ≥90%.43   
 
 
 
  
 
  
Chapter 3.  Maternal weight loss during exclusive breastfeeding is associated with 
reduced weight and length gain in daughters of HIV-infected Malawian women  
 
Overview 
Maternal weight loss during exclusive breastfeeding may influence growth of 
exclusively breastfed infants through impaired quality or quantity of breastmilk. This study 
evaluated how maternal weight loss from 2-24 wk was related to infant weight and length 
gain in 1,390 lactating HIV-infected mothers and their exclusively breastfed infants. 
Malawian mother-infant pairs in the Breastfeeding, Antiretrovirals, and Nutrition (BAN) 
study were randomized to receive a lipid-based nutrient supplement (LNS), meeting 
nutritional needs of lactation, or no LNS and a maternal, infant or no antiretroviral (ARV) 
regimen. Linear regression models were used to relate maternal weight loss (weight loss vs. 
no weight loss) to infant weight and length gain from birth to 24 wk, stratifying by gender, 
and controlling for infant birthweight/length and  maternal BMI at 2 wk (mean: 23.1 kg/m2) 
and interacting maternal BMI with weight loss. Length (β: -3.24 cm, p=0.01) and weight gain 
(β: -1.21 kg, p=0.008) were lower in girls whose mothers had lower BMI at 2 wk postpartum 
coupled with the weight loss, compared to girls of women who did not lose weight. Though 
associations were only observed in girls, suggesting possible gender differences in suckling 
and feeding behavior, these findings indicate that maternal weight loss with low energy 
reserves represents a risk factor for poor infant growth outcomes. 
. 
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Introduction 
  During exclusive breastfeeding, the mother is the sole source of nutrition for her 
infant. Breastfeeding can deplete energy and nutrient reserves of women with  inadequate 
dietary intake and very poor maternal nutrition can impair breastmilk quantity and nutrient 
quality.8,18-20 Increases in maternal weight during lactation have previously been linked to 
improved quantity and nutrient quantity of breastmilk in marginally nourished Bangladeshi 
women;20 yet, it is not well understood how these weight changes translate into breastmilk 
output and infant growth due to the complex nature of this relationship.8  
  Maternal breastmilk supply is regulated to match infant demand through frequency 
and intensity of infant suckling.8,44 With increased infant demand, maternal breastmilk 
production will increase. In the absence of adequate dietary intake to meet the energy costs of 
lactation and due to hormonal influences of lactation, maternal fat stores may be mobilized to 
meet the demand—with implications for maternal weight changes.8 Increased milk intake 
will subsequently influence infant growth and may lead to further rises in infant demand and 
additional burden on maternal nutritional status, as a rapidly growing infant will likely 
demand more milk.8 Given adequate maternal nutrient stores and dietary intake, most women 
may be able to meet infant breastmilk demand; however, in cases where mothers are 
undernourished and are losing weight, breastmilk energy output may decrease if the mother 
exceeds her lactational capacity (the ability to produce milk on demand),9 which could 
adversely affect infant growth.  
  In resource-poor settings with high HIV prevalence, six months of exclusive 
breastfeeding by HIV infected women is recommended to promote child survival if 
replacement feedings are not acceptable, feasible, affordable, sustainable and safe.45 Since 
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HIV infection and lactation increase metabolic demands,46 lactating HIV infected women 
may be unable to simultaneously meet their own and their infant’s nutritional needs; thus 
understanding how maternal weight changes during lactation influence infant growth may be 
especially important for promoting health and survival of the mother-infant dyad in the 
context of HIV.  
  During the first six months postpartum, most lactating women experience mild and 
gradual weight loss.12 Even among well-nourished women, breastfeeding is usually 
associated with earlier return to pre-pregnancy weight, but has also been associated with 
weight gain and weight maintenance.13,14 Among undernourished women, weight loss, 
weight maintenance and even moderate weight gain have been reported.15-18 Anthropometry 
patterns during lactation have been less well described in HIV infected women. Similar to 
HIV uninfected women, though, the findings are inconsistent with studies reporting both 
weight gains and losses during lactation.13   
  Although few studies have reported how the overall pattern of maternal weight 
changes during breastfeeding influence infant growth, there is evidence of associations 
between maternal and infant anthropometry in HIV-uninfected and HIV-infected 
populations. In Indonesian mother-infant pairs, increasing maternal post-partum body mass 
index (BMI) (kg/m2), measured between 4-6 months, was associated with higher infant 
weight and length gains between birth and 6 months.26 In Bolivian mother-infant pairs, 
maternal weight and height at 3 months postpartum were positively correlated with infant 
weight gain between 3 and 6 months.27 In thirty-five low income Indian women, a 1 kg loss 
in maternal fat mass from baseline (measured within 1 month of birth) to 6 months 
postpartum was associated with 107 gram higher infant weight gain (p=0.04) at 6 months, 
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after controlling for baseline maternal weight, infant birthweight and changes in maternal 
appendicular skeletal mass.47  In HIV-infected and uninfected mothers and infants in Kenya 
ages 4 to 24 mo, higher maternal weight was associated with higher concurrently measured 
length-for-age (LAZ), weight-for-age (WAZ) and weight-for-length (WLZ) z-score, while 
higher maternal height was associated with higher LAZ and WAZ.48 Higher maternal BMI 
and mid-upper-arm circumference was associated with higher WAZ and WLZ.48 To better 
understand the relationship between maternal weight changes and infant growth, it may be 
important to evaluate how the overall pattern of maternal weight change influences infant 
growth. 
  Our objective was to examine the how maternal weight loss from 2 to 24 wk relates to 
infant growth from 0 to 24 wk, corresponding with exclusive breastfeeding in a large sample 
of mother-infant pairs participating in the Breastfeeding, Antiretrovirals, and Nutrition 
(BAN) study. The Malawi Mothers and Infants (MaMi) study is an analysis of 
anthropometric and nutrition data from the BAN study.  Mothers in the BAN study who 
received lipid based nutrient supplement (LNS) had less weight loss during the exclusive 
breastfeeding (0-24 wk), than mothers who did not receive LNS regardless of antiretroviral 
drug assignment.49 In this paper, we examine how infant weight and length gain are 
influenced by the net change in maternal weight during lactation. We assume infant growth is 
a proxy indicator of lactation adequacy.50 To provide contextual background for our findings, 
we also examined how the maternal weight loss was influenced by BAN treatment arm, 
parity, and seasonality. We hypothesized that the effects of maternal weight loss on infant 
weight and length gain will depend on initial energy stores, with more detrimental effects if 
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the mother has limited stores to mobilize. We expected to observe similar effects on infant 
weight gain and linear growth.  
Methods 
  The BAN study design has been described in detailed elsewhere.51 Briefly, BAN was 
a randomized controlled trial of 2,369 mother-infant pairs that was conducted from April 
2004 to February 2010 in Lilongwe, Malawi. HIV 1-positive pregnant women (n=3572) were 
recruited from four antenatal clinics. Initial screening criteria included: age ≥ 18 years (or 
≥14 years of age if married), CD4 count ≥ 250 cells/µL (prior to 11/13/2006 CD4 cut off was 
≥200 cells/µL),  hemoglobin (Hb) ≥ 7 g/dL, no prior antiretroviral medication use, and no 
major pregnancy complications.1 Eligible women (n=2791) who delivered at the study site 
were provided with maternal and infant single dose nevirapine peripartum as well as twice-
daily zidovudine and lamivudine for 7 days postpartum. Within 36 hours after delivery 
mother-infant pairs had to present at the study site and meet secondary eligibility criteria for 
randomization: infant birthweight ≥ 2 kg, no severe congenital malformations, no other 
conditions incompatible with survival or that would preclude the use of the study drugs. 2382 
mother-infant pairs met these criteria and thirteen women declined further participation. 2369 
women completed informed consent and were randomized using a permuted-block method to 
one of six treatment arms according to a two-arm nutritional and three-arm antiretroviral 
factorial design. Half of the mothers received daily maternal LNS providing estimated added 
energy and protein requirements of lactation as well as the recommended daily allowance of 
micronutrients, excluding vitamin A. Mother-infant pairs were further randomized to 
maternal or infant antiretroviral drug, or no post-natal antiretroviral regimen. Details 
regarding the LNS and drug regimens are described elsewhere.49 Randomized infants 
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diagnosed with HIV-1 within two wk of delivery (n=119) with polymerase chain reaction 
(PCR) were withdrawn from the study, and mother-infant pairs were referred for care.1 In 
June 2006, the BAN study initiated cotrimoxazole preventive therapy for infants 6-36 wk of 
age, based on WHO recommendations.52  
  To buffer the effects of seasonal food shortages and to prevent sharing of maternal 
LNS, all participants were given 2 kg of maize per week for family consumption. During a 
drought from February to August 2005, the World Food Program (WFP) provided food aid to 
all HIV-infected women in Lilongwe, consisting of a monthly ration of corn/soy flour—
similar to the quantity in the BAN maize supplement—and 1 liter of vitamin-A-fortified corn 
oil. This was provided in lieu of the BAN maize package to an estimated 260 BAN mothers 
and was evenly distributed across study arms.32  
  In accordance with the World Health Organization prevention of maternal to child 
transmission of HIV (PMTCT) guidelines when the study was designed, 53 all BAN mothers 
were provided intensive counseling to exclusively breastfeed their infants for 24 wk and to 
rapidly wean by 28 wk.43 Only data up to 24 wk are included in this analysis, corresponding 
with the period of exclusive breastfeeding.  
The Malawi National Health Science Research Committee and the institutional 
review boards at University of North Carolina at Chapel Hill and the U.S. Centers for 
Disease Control and Prevention approved the BAN protocol.  
Anthropometrics and study procedures 
  Study visits and data collection were conducted at the BAN study clinic at Bwaila 
Hospital in Lilongwe. Mother-infant pairs were followed at birth and 2, 4, 6, 8, 12, 18, 21, 
and 24 wk postpartum. At all visits, maternal and infant weight was measured to the nearest 
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0.1 kg unit using Tanita digital electronic scales, which were calibrated regularly. Maternal 
height was measured with a wall-mounted stadiometer. Infant recumbent length was 
measured using a wooden length board made to UNICEF specifications.54 Nurses and 
nutrition assistants were trained in anthropometrics and their measurements were obtained 
using standard methods.54 
Infant HIV status was tested with Amplicor 1.5 DNA PCR at 0, 2, 12 and 28 wk. 
Postnatal HIV tests were confirmed with a specimen obtained at the following visit. Dried 
blood spots, collected at all study visits excluding the visit at 21 wk, were tested using Gen-
Probe Aptima HIV-1 Qualitative assay to further refine the timing of infection in infants with 
positive PCR results.  
  Maternal report of parity, marital status, and years of maternal education was 
obtained at the screening visit. Maternal report of infant’s exclusive breastfeeding status was 
obtained at 4, 8, 12, 18, 21 and 24 wk postpartum. Maternal report of maternal and infant 
morbidity occurring prior to the visit was obtained at each visit. Physician report of maternal 
or infant illness was obtained if the mother reported illnesses. 
  Malawi has a subtropical climate with four seasons: cool (May to mid-August), hot 
(mid-August to November), rainy (November to April) and post-rainy (April to May). 
Availability of food, malnutrition and morbidity due to infectious disease vary by season due 
to rainfall and agricultural production.55 Season of poor food security is generally from 
November/December to March/April. This period is characterized by limited food 
availability, as crop stores are depleted.  
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Statistical Analyses 
  Due to normal physiologic changes in the immediate post-partum period and the 
various factors that could potentially influence the maternal weight measurement at delivery 
(edema, timing of measurement relative to delivery), we analyze the pattern of maternal 
weight change from 2 to 24 wk. For simplicity of interpretation and to test the theory 
proposed by Brown and Dewey,9 where women with insufficient energy reserves will have 
suboptimal milk energy output if they are losing weight,9 we utilized a dichotomous maternal 
weight change pattern (weight loss vs. no weight loss) in this analysis. Maternal weight at 2 
weeks was subtracted from maternal weight at 24 weeks to determine whether the mother 
was losing weight (weight change <0) or not losing weight (weight change ≥0) during 
exclusive breastfeeding. Alternate specifications of maternal weight change, as a continuous 
and categorical variable (tertiles and quartiles of maternal weight change), were examined as 
potential primary exposure variables.  Compared to the categorical weight loss (weight loss 
vs. no weight loss), continuous maternal weight change and quantile categories (tertiles and 
quartiles) were observed to have similar model fit and effects. 
Infant growth models evaluated the influence of maternal weight loss, controlling for 
infant initial anthropometric measurement, and maternal body mass index (BMI) at 2 wk 
postpartum. The interaction term between maternal BMI and maternal weight loss tested 
whether the effects of maternal weight loss varied by initial maternal energy reserves. 
Adjusted models also included seasonality, parity, BAN treatment arm, education and 
maternal CD4 count. Adjusted models also included infant morbidity from birth to 24 weeks 
including fever, vomiting and diarrhea. Illnesses were modeled as the number of instances of 
illness over number of visits from 0 to 24 weeks. Infant growth models were gender stratified 
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given the significant gender differences observed in infant weight and length gain, and a 
significant three-way interaction between maternal weight loss, maternal BMI and gender in 
the adjusted infant growth models (Length gain interaction p=0.04; Weight gain interaction 
p=0.08).  
Logistic regression was used to evaluate predictors of maternal weight loss, including 
seasonality, parity, BAN treatment arm, education and maternal CD4 count. Seasonality was 
measured as month of birth in order to allow us to estimate the pattern of seasonal effects on 
maternal and infant anthropometry. Birth month allows us to understand the timing of 
maternal exposure to food insecurity during pregnancy, as well as food availability to the 
mother following delivery. October was selected as the referent birth month, as mothers were 
not exposed to periods of food insecurity during the latter part of pregnancy, but were 
exposed during breastfeeding. Given no observed differences in the likelihood of maternal 
weight loss between the months of Sept-Nov (p>0.1), these months were combined together 
as the reference month for seasonality. 
  Mother-infant pairs were included in the analysis sample if they had data at 0 and 24 
wk for the infant, and 2 and 24 wk for the mother. Multiple births (n=49) were excluded from 
this analysis, as multiples exhibit different growth patterns than singletons and mothers of 
multiples have different gestational weight gain and postpartum weight change patterns.56  
Infants who were mixed fed or weaned prior to 24 wk (n=248) were also excluded, as the 
mother was no longer the sole source of nutrition for her infant.  Owing to differences in 
growth and nutrient dynamics of HIV infected infants, HIV infected infants (n=58) 
diagnosed after 2 wk postpartum were excluded.1 A small number (n=6) of implausible infant 
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weights and lengths at 24 wk were replaced by values interpolated from prior and subsequent 
measurements. Statistical analyses were conducted with STATA 12.1 (College Station, TX). 
Results 
Mean weight loss of mothers from 2 to 24 wk was 0.93 kg (SD: 3.4 kg) (Table 3.1). 
63.3% of mothers lost weight from 2 to 24 weeks, while 36.7% gained weight or had no 
weight changes during this period. The proportion of mothers receiving the LNS did not 
differ between the weight loss and no weight change groups (p=0.85). Of the women that lost 
weight (n=829), mean weight loss was 2.5 kg. Of the mothers that gained weight (n=469), 
mean weight gain was 2 kg from 2 to 24 wk.  
  Maternal weight loss was associated with less length and weight gain in girls, 
particularly among mothers with lower BMI values at 2 wk (Table 3.2; Figure 3.1). Effects of 
maternal weight loss were strengthened after adjusting for confounders. Maternal weight loss 
from 2 to 24 wk had no effects on weight or length gain in boys (p>0.05), even at varying 
BMI levels in adjusted and unadjusted models (Figure 3.1). In adjusted models, few factors 
significantly influenced infant weight and length gain from birth to 24 wk (Table 3.2), 
consistent with previous findings in BAN infants.32 Higher birth length was associated with 
decreased length gain in boys and girls. Maternal ARV treatment was associated with lower 
length gain in boys and girls, while infant ARV treatment was associated with lower length 
gain only in girls. Maternal LNS was not associated with infant weight or length gain. July 
birth was associated with greater weight gain in boys and girls. Other than July, only 
February was associated with increased weight gain, but only in girls (p=0.02). For boys, 
January births were associated with decreased length gain (p=0.03). August births were 
associated with increased length gain in girls (p=0.003).  
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Taller maternal height (p=0.04) and the maternal ARV arm (p<0.001) were associated 
with increased odds of maternal weight loss, while the LNS intervention, primiparity, low 
CD4 count, and maternal BMI at 2 wk were not associated with the likelihood of maternal 
weight loss (Table 3.3). Birth month was significantly associated with maternal weight loss 
[χ2 (9) =81.33, p<0.001]. Compared to Sept-Nov, births from January to June were 
associated with reduced odds of weight loss (all p-values <0.001).  
Sensitivity analyses showed that  including HIV infected infants who had maternal 
and infant weight data at birth, 2 wk and 24 wk and were still exclusively breastfed at 24 wk 
(n=28) did not influence the interpretation of results.  
Discussion 
   In our population, we expected to observe adverse effects of low maternal BMI in 
both boys and girls; however, lower maternal BMI only adversely affected the growth of 
girls. Initial maternal BMI was not different by infant gender; but mothers of boys lost 
marginally more weight than mothers of girls (p=0.07). Given our differential findings by 
gender, it appears that the milk production of undernourished mothers of girls could have 
been limited by substrates available for milk biosynthesis or their lactational capacity.8   
Perhaps mothers of boys with lower BMIs were better able to mobilize existing nutrient 
stores or dietary intake into breastmilk production than mothers of girls; yet we are unable to 
test this as we do not have macronutrient content of breastmilk. Gender preferences in 
feeding practices are unlikely to explain our findings, as there is little prior evidence of 
gender preferences in Malawi.57 
   The observed gender differences in maternal weight loss effects are in contrast to 
what was expected, as boys gain weight and length more rapidly than girls,58 which may 
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enhance their susceptibility to environmental insults, such as suboptimal breastmilk quality 
and quantity. Boys are more vulnerable to undernutrition in utero, as they have faster growth 
rates and their placentas are believed to have less reserve capacity compared to girls.59 As a 
result of this fetal environment, boys may be programmed to be more adaptive to nutritional 
insults postpartum, and may have an enhanced ability to demand more milk through suckling 
and feeding behavior despite suboptimal maternal milk output.  
  Though previous studies have reported associations between maternal weight change 
and quantity and energy content of milk,20 sex differences in milk energy output have not 
been reported in humans. In rhesus macaques, mothers of males, especially if primiparous 
produced more energy dense, high fat milk, but produced less milk overall, compared to 
mothers of females.60 Though mothers produced similar milk energy amounts between males 
and females, it is unclear whether reduced quantity but higher energy content adversely 
affects growth.60 As higher breastmilk energy and protein consumption has been observed to 
positively influence infant growth,20 our observed sex differences could possibly be 
attributable to sex differences in human milk energy output. 
  Notably few factors influenced infant weight and length gain in the adjusted models, 
consistent with previous findings in BAN infants.32 Since BAN infants were exclusively 
breastfed, a requirement for inclusion in this analysis, this suggests that previously observed 
predictors of infant growth such as seasonality and parity are not as influential when the 
infant is exclusively breastfeeding. Exclusive breastfeeding appears to buffer the adverse 
effects of seasonality on infant weight and length gain. Infant breastmilk intake was observed 
to decline during the rainy season in The Gambia, which is when mothers usually lose 
weight,61 and was initially attributed to maternal energy restriction.61 However, dietary 
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supplementation of lactating women in a subsequent study had no effects on maternal milk 
volume in The Gambia.61 Given these findings and additional studies reporting seasonal 
variations breastmilk intake in Kenya and Zaire, the authors concluded that the observed 
seasonal variations in breastmilk output were attributed to increased infant morbidity and 
altered breastfeeding patterns due to strenuous maternal farm work.61 Since BAN infants 
were closely followed and treated for illnesses throughout the study, seasonal morbidity 
effects on breastmilk intake could have been limited. Moreover, mothers were intensively 
counseled to exclusively breastfeed. As such, their infants were protected by the 
immunological components of milk and were not exposed to pathogens through 
contaminated foods and fluids. In adjusted models, most morbidities were not predictors of 
infant weight or length gain. In the length gain adjusted models, vomiting was associated 
with diminished length gain only in the boys.   
  Similar to other studies in HIV infected and non HIV-infected populations, maternal 
weight change patterns were heterogeneous during exclusive breastfeeding with some 
mothers losing and others gaining weight.12,16 While taller stature was associated with the 
maternal weight loss, the likelihood of weight loss was not related to initial BMI. 
Primiparity, low CD4 count, marital status and education beyond primary school were not 
associated with maternal weight loss. Though maternal CD4 count has previously been 
associated with weight loss in a population of breastfeeding HIV-infected Zambian women,13 
inclusion requirements for BAN (CD4>250 cells/µL) may have reduced our ability to 
observe negative effects of low maternal CD4. The maternal ARV intervention was 
associated with weight loss from 2 to 24 wk. One of the drugs in the BAN regimen was 
lopinavir/ritonavir (Kaletra), which is frequently associated with diarrhea. As such, diarrhea 
       27 
may have contributed to the weight loss in this group.6262  Maternal LNS had no association 
with maternal weight loss from 2 to 24 wk postpartum. Though LNS was found to have a 
small protective effect on maternal weight loss from 0 to 28 wk in an intent-to-treat analysis 
of BAN mothers (n=2369) the difference between treatment arms was reported to be of little 
clinical importance;49 our lack of LNS findings is not surprising given our much smaller 
analytic sample (n=1309) and our focus on only the period of exclusive breastfeeding from 2 
to 24 wk. Mothers who gave birth from January through June were protected from being in 
the maternal weight loss group. These women were exposed to food insecurity during 
pregnancy and in the postpartum period, but were not as exposed to food insecurity for the 
duration of their postpartum weight changes, compared to mothers of infants born between 
Sept and November. Though many factors influenced the odds of maternal weight loss, few 
of these factors affected infant weight and length gain; which indicates that maternal 
breastmilk output was sufficient to mitigate the effects of these factors, even though the 
mother was losing weight.  
This research has some limitations. First, we only had available data on maternal and 
infant weight and length, and did not have detailed information on body composition, which 
would have allowed us to understand how changes in maternal body composition related to 
infant growth and body composition. Effects of maternal weight change on infant growth are 
likely mediated through breastmilk quantity and quality, which was not measured in this 
study. Second, we excluded about 45% of randomized mother-infant pairs from our analysis 
who were lost to follow-up (n=620), multiple births (n=49), weaned early (n=248) or HIV 
infected infant in first 2 wk (n=199) or HIV-infected infant from 2 to 24 wk (n=58). 
Compared to randomized infants who were not included in the analysis sample (n=1060), 
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infants included in our analysis (n=1309) had higher birthweight (p=0.005), lower prevalence 
of low birth weight (p=0.009), higher birth length (p=0.002) and were more likely to receive 
the ARV intervention (p=0.006); however, there were no differences between included and 
excluded infants in infant gender (p=0.14) or Hb at birth (p=0.96). As worse off infants were 
lost-to-follow up or excluded, we may have underestimated the effects of maternal weight 
changes on infant growth.  
This study also has many strengths. Applying a dyadic modeling framework is an 
innovative approach to examine these mother-infant anthropometry relationships. Supporting 
this analysis approach are the detailed exclusive breastfeeding data, which allowed us to 
exclude weaned and mixed fed infants from our analyses, as the mother was no longer the 
sole source of nutrition for her growing infant. Moreover, our analysis focused on the period 
of the most rapid infant weight and length gain and highest maternal energy demands, 
enhancing our ability to observe effects of maternal weight loss. Finally, understanding these 
relationships is especially important in the context of HIV in order to guide future 
interventions and programs to promote maternal and infant health.  
In conclusion, our findings suggest that maternal weight loss coupled with low energy 
reserves may adversely affect infant growth. Further research to understand this relationship 
is indicated, especially to determine why effects were only seen in girls.  
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Table 3.1 Characteristics of 1,309 BAN mother-infant pairs in the primary analysis of 
the effects of maternal weight loss on infant growth 
MOTHERS  
Age (y)1 26.7 ± 5.1 
Height (cm)1 156.9 ± 5.5 
Weight (kg)1 56.2 ± 8.8 
Maternal body mass index (kg/m2)1 22.8 ± 3.2 
Primiparous (%)  9.6 
Married (%)  92.3 
Education beyond primary school (%) 36.1 
Hemoglobin (g/dL) 1,2 10.9 ± 1.2 
CD4 count (cells/µL)1,2 475.4 ± 195.7 
CD4 <350 cells/µL (%)2 29.9 
Received ARV (%) 35.8 
Received LNS supplement (%) 51.8 
Maternal weight change from 2 to 24 wk(kg)1 -0.93 ± 3.4 
  
INFANTS   
Male gender (%) 51.5 
Birth weight (kg)1 3.04 ± 0.40 
Low birth weight (%)3 6.0 
Birth length (cm)1 48.3 ± 1.9 
Hemoglobin at birth (g/dL)1  17.4 ± 2.01 
Received ARV (%) 38.4 
Weight gain from birth to 24 wk (kg)1 4.13 ± 0.82 
Length gain from birth to 24 wk (cm)1 15.7 ± 2.2 
1Mean +/- SD (all such values) 
2 Measured during pregnancy 
3Low birth weight 2-2.5 kg as infants had to weigh ≥2.0 kg to be eligible for BAN 
BAN, Breastfeeding Antiretoviral and Nutrition; LNS, lipid-based nutrient supplement; ARV, antiretroviral 
intervention.   
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Table 3.2 Gender stratified linear regression models showing the effects of maternal weight loss on infant weight and length 
gain from 0 to 24 wk 
  Weight gain (kg)   Length gain (cm) 
  
Crude 
  
Adjusted 
   
Crude 
  
Adjusted 
 
 
Coef 95% CI p-value Coef 95% CI p-value 
 
Coef 95% CI p-value Coef 95% CI p-value 
BOYS 
 
n=673 
  
n=653 
   
n=667 
  
n=647 
 Birth measurement -0.20 [-0.35,-0.04] 0.01 -0.15 [-0.31,0.01] 0.06 
 
-0.42 [-0.51,-0.34] <0.001 -0.43 [-0.51,-0.35] <0.001 
Mom lost weight -0.10 [-1.12,0.92] 0.84 -0.09 [-1.14,0.97] 0.87 
 
1.30 [-1.30,3.90] 0.33 1.50 [-1.15,4.14] 0.27 
Maternal BMI at 2 wk 0.03 [-0.003,0.07] 0.08 0.02 [-0.02,0.06] 0.27 
 
0.07 [-0.02,0.16] 0.13 0.06 [-0.03,0.15] 0.20 
Mom lost *Mom BMI 0.01 [-0.04,0.05] 0.79 0.01 [-0.04,0.05] 0.82 
 
-0.06 [-0.17,0.05] 0.30 -0.07 [-0.18,0.05] 0.26 
CD4 <350 
   
0.06 [-0.08,0.20] 0.39 
    
0.12 [-0.24,0.47] 0.52 
Fever 
   
-0.03 [-0.10,0.04] 0.37 
    
0.16 [-0.004,0.33] 0.06 
Vomiting 
   
-0.01 [-0.15,0.12] 0.83 
    
-0.38 [-0.72,-0.05] 0.03 
Diarrhea 
   
-0.05 [-0.17,0.06] 0.38 
    
0.15 [-0.14,0.45] 0.31 
Primiparous 
   
0.01 [-0.22,0.24] 0.91 
    
-0.25 [-0.82,0.32] 0.39 
Birthmonth (ref: Sept-Nov) 
           January  
   
-0.12 [-0.38,0.14] 0.36 
    
-0.76 [-1.40,-0.11] 0.02 
February  
   
0.05 [-0.20,0.30] 0.71 
    
-0.22 [-0.85,0.41] 0.49 
March  
   
0.22 [-0.04,0.48] 0.10 
    
0.17 [-0.49,0.82] 0.61 
April  
   
-0.03 [-0.29,0.23] 0.80 
    
-0.21 [-0.87,0.45] 0.54 
May  
   
0.01 [-0.22,0.25] 0.92 
    
0.17 [-0.42,0.77] 0.57 
June  
   
-0.11 [-0.36,0.14] 0.40 
    
-0.26 [-0.89,0.37] 0.42 
July  
   
0.30 [0.06,0.55] 0.02 
    
0.30 [-0.33,0.92] 0.35 
August  
   
0.17 [-0.09,0.42] 0.20 
    
0.50 [-0.15,1.15] 0.13 
Dec  
   
0.03 [-0.22,0.28] 0.80 
    
-0.20 [-0.82,0.43] 0.54 
Married 
   
0.17 [-0.06,0.39] 0.15 
    
0.12 [-0.46,0.69] 0.69 
Education 
   
0.0005 [-0.13,0.13] 0.99 
    
0.31 [-0.02,0.64] 0.07 
Mom ARV 
   
-0.13 [-0.29,0.04] 0.12 
    
-0.59 [-1.00,-0.18] 0.01 
Mom LNS 
   
0.07 [-0.06,0.19] 0.29 
    
-0.03 [-0.35,0.29] 0.88 
Kid ARV 
   
-0.07 [-0.23,0.09] 0.42 
    
-0.25 [-0.65,0.15] 0.22 
Intercept 4.16 [3.29,5.02] <0.001 4.16 [3.23,5.09] <0.001 
 
35.04 [30.75,39.34] <0.001 35.48 [31.04,39.91] <0.001 
              GIRLS 
 
n=633 
  
n=609 
   
n=632 
  
n=608 
 Birth measurement -0.26 [-0.43,-0.10] 0.002 -0.30 [-0.47,-0.13] 0.001 
 
-0.46 [-0.55,-0.37] <0.001 -0.46 [-0.56,-0.36] <0.001 
Mom lost weight -0.97 [-1.86,-0.08] 0.03 -1.29 [-2.20,-0.38] 0.01 
 
-2.38 [-4.83,0.08] 0.06 -3.36 [-5.88,-0.85] 0.01 
Maternal BMI at 2 wk 0.03 [-0.001,0.06] 0.06 0.02 [-0.01,0.05] 0.12 
 
-0.005 [-0.08,0.07] 0.90 -0.03 [-0.11,0.05] 0.49 
Mom lost *Mom BMI 0.04 [0.004,0.08] 0.03 0.06 [0.02,0.09] 0.01 
 
0.1 [-0.01,0.20] 0.07 0.14 [0.03,0.25] 0.01 
CD4 <350 
   
0.03 [-0.10,0.16] 0.70 
    
-0.19 [-0.55,0.17] 0.31 
Fever 
   
0.01 [-0.06,0.07] 0.84 
    
0.11 [-0.07,0.28] 0.23 
Vomiting 
   
-0.0005 [-0.13,0.13] 1.00 
    
-0.01 [-0.38,0.37] 0.98 
Diarrhea 
   
-0.03 [-0.16,0.10] 0.63 
    
-0.003 [-0.36,0.35] 0.99 
30
 
       31 
Primiparous 
   
-0.13 [-0.34,0.07] 0.20 
    
0.21 [-0.35,0.76] 0.46 
Birthmonth (ref: Sept-Nov) 
   
 
       January  
   
0.04 [-0.21,0.28] 0.78 
    
0.04 [-0.66,0.73] 0.92 
February  
   
0.32 [0.05,0.59] 0.02 
    
0.66 [-0.09,1.41] 0.08 
March  
   
-0.02 [-0.28,0.24] 0.87 
    
-0.32 [-1.05,0.41] 0.39 
April  
   
0.14 [-0.11,0.39] 0.26 
    
-0.08 [-0.78,0.61] 0.82 
May  
   
0.09 [-0.14,0.32] 0.43 
    
0.35 [-0.28,0.98] 0.27 
June  
   
0.17 [-0.06,0.39] 0.14 
    
0.64 [0.02,1.26] 0.04 
July  
   
0.42 [0.17,0.66] 0.001 
    
0.16 [-0.52,0.84] 0.64 
August  
   
0.13 [-0.09,0.35] 0.25 
    
0.88 [0.28,1.49] 0.004 
Dec  
   
0.23 [-0.04,0.49] 0.09 
    
0.21 [-0.52,0.94] 0.57 
Married 
   
-0.05 [-0.29,0.19] 0.70 
    
0.10 [-0.56,0.76] 0.77 
Education 
   
0.05 [-0.08,0.18] 0.42 
    
0.16 [-0.20,0.52] 0.38 
Mom ARV 
   
-0.04 [-0.20,0.11] 0.58 
    
-0.43 [-0.87,0.02] 0.06 
Mom LNS 
   
0.08 [-0.05,0.20] 0.22 
    
0.21 [-0.12,0.55] 0.21 
Kid ARV 
   
-0.11 [-0.26,0.05] 0.18 
    
-0.58 [-1.01,-0.15] 0.01 
Intercept 4.06 [3.32,4.80] <0.001 4.22 [3.42,5.01] <0.001 
 
37.64 [33.07,42.21] <0.001 38.03 [33.21,42.86] <0.001 
BAN, Breastfeeding Antiretoviral and Nutrition; LNS, lipid-based nutrient supplement; RV, antiretroviral intervention
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Table 3.3 Predictors of maternal weight loss among BAN mothers 
Maternal weight loss from 2-24 wk1 
OR 95% CI p 
BMI at 2 weeks postpartum 1.02 [-0.02,0.06] 0.32 
Maternal height (cm) 1.02 [0.00,0.04] 0.04 
CD4 <350 cells/µL 1.14 [-0.13,0.40] 0.33 
Primiparous 1.01 [-0.41,0.43] 0.96 
Birthmonth (ref: Sept, Oct, Nov)2 
January 0.35 [-1.52,-0.56] <0.001 
February 0.32 [-1.62,-0.64] <0.001 
March 0.19 [-2.16,-1.17] <0.001 
April 0.29 [-1.74,-0.77] <0.001 
May 0.35 [-1.51,-0.62] <0.001 
June 0.42 [-1.34,-0.41] <0.001 
July 1.05 [-0.48,0.59] 0.85 
August 0.77 [-0.75,0.23] 0.30 
December 0.62 [-0.99,0.03] 0.07 
Married 1.49 [-0.05,0.84] 0.08 
Education 1.22 [-0.06,0.46] 0.13 
Mom ARV 1.74 [0.29,0.81] <0.001 
Mom LNS 0.98 [-0.26,0.22] 0.87 
Intercept 0.03 [-7.11,0.11] 0.06 
1Maternal weight loss from 2-24 wk, compared to weight change ≥0 
2Chunk test for season effects: chi2(9) 81.33, p<0.001 
BAN, Breastfeeding Antiretoviral and Nutrition; LNS, lipid-based nutrient supplement; ARV, antiretroviral 
intervention.   
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Infant weight gain from 0-24 wk (kg) 
 
 
Infant length gain from 0 to 24 wk (cm) 
 
Figure 3.1 Predicted infant weight gain and length from 0 to 24 weeks for varying 
maternal BMI levels 
Predicted values of infant weight and length gain from 0 to 24 weeks from a linear regression 
model relating maternal weight loss at varying maternal BMI levels at 2 weeks postpartum to 
infant growth outcomes at 24 weeks. Predicted values at each BMI level represent the linear 
combination of maternal weight loss coefficient, maternal BMI coefficient and the interaction 
between maternal weight loss and BMI coefficients. Each model also contained the infant’s 
birth measurement for weight (p=0.01) in the weight gain model and length (p<0.001) in the 
length gain model. BMI, body mass index. 
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Chapter 4. Maternal transferrin receptors and ferritin are associated with infant values 
in exclusively breastfed HIV-exposed infants 
 
 
Overview 
  Infant iron status at birth is influenced by maternal iron status during pregnancy; 
whether maternal iron status is associated with infant iron status during exclusive 
breastfeeding is controversial. We evaluated how maternal and infant hemoglobin (Hb) and 
iron status [transferrin receptors (TfR) and ferritin] were related during exclusive 
breastfeeding in HIV-infected women and their infants. The BAN (Breastfeeding, 
Antiretrovirals and Nutrition) Study was a randomized controlled trial in Lilongwe, Malawi, 
where HIV-infected women were assigned with a 2 x 3 factorial design to lipid-based 
nutrient supplements (LNS), or no LNS, and maternal antiretrovirals (ARV), infant ARV or 
no ARV. We used longitudinal models to relate maternal Hb (n=1926) to concurrently 
measured infant Hb. In a subsample, we regressed change in infant iron status (Hb, log 
ferritin, log TfR) between 2 (n=355) or 6 wk (n=167), and 24 wk (n=532) on corresponding 
change in maternal indicator, adjusting for initial values. A one-unit higher maternal Hb at 6, 
12, and18 wk was associated with 0.04 g/dL (p=0.02), 0.07 g/dL (p=0.001), and 0.05 g/dL 
(p=0.008) respective higher value in infant Hb. In the subsample, an increase in maternal TfR 
and Hb was associated with a respective increase in infant values (TfR β: 0.18 mg/L, 
p<0.001; Hb: β: 0.13 g/dL, p=0.01). Initial infant values were strong predictors of later infant 
Hb and iron status (all p-values <0.001). Given the observed maternal influence and the 
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influence of initial infant values, optimizing maternal iron status is important to protect infant 
iron status. 
Introduction 
  Iron deficiency is the most common nutrient deficiency in low-income countries and 
is associated with increased perinatal and maternal mortality, and impaired infant growth, 
neurodevelopment, and immune function. Given the initial iron endowment at birth, to date 
the predominant opinion has been that infant iron stores are sufficient during exclusive 
breastfeeding from birth to 6 months.63 However, infants in resource poor settings are prone 
to early depletion of iron stores, especially if maternal iron status was poor before or during 
pregnancy,33 and among infants with shorter gestational age,33 low birthweight,64,65 male 
gender,64 and rapid growth.33 The identification of postnatal factors that influence infant’s 
risk of early iron store depletion and subsequent deficiency is urgently needed.  
  Whether maternal iron status is associated with infant iron status during 
breastfeeding—independent of infant iron stores at birth—is unclear. Studies evaluating the 
impact of maternal iron status during lactation on breast milk iron content have been 
inconsistent.66-70 Several recent studies have shown that maternal Hb and serum iron levels 
are related to breastmilk iron levels, especially in anemic women or women with impaired 
iron status markers;69,70,70-72 however, studies that have investigated whether breastmilk iron 
levels subsequently influence infant iron status are equivocal.72  
  Understanding the relationship between mother and infant iron status is especially 
important in the context of HIV. HIV-infected women are at high risk of anemia during 
pregnancy and of depleted iron stores postpartum.36,37 In resources poor settings, six months 
of exclusive breastfeeding by HIV-infected women coupled with antiretroviral prophylaxis to 
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the mother or infant is recommended to promote child survival and prevent mother-to-child 
transmission of HIV if replacement feedings are not acceptable, feasible, affordable, 
sustainable and safe.45 Together, these factors—impaired maternal iron status, antiretroviral 
prophylaxis,73and exclusive breastfeeding—may result in early depletion of infant iron stores 
and possibly a greater dependency on breastmilk iron as lactation proceeds.  
  Our objective was to examine the relationship between maternal and infant 
hemoglobin (Hb) and iron status (ferritin and TfR), and furthermore because this was part of 
a randomized controlled trial, to determine the effects of the study interventions on maternal 
and infant Hb in participants of the Breastfeeding, Antiretrovirals and Nutrition Study (BAN) 
and a subset of BAN participants selected for additional biomarker assays, the Malawi 
Mothers and Infants (MaMi) subsample. BAN mother-infant pairs were randomized to a 2-
arm nutritional intervention with maternal lipid-based nutrient supplementation (LNS) 
meeting the nutritional needs of lactation and providing 15 mg iron per day and to a 3-arm 
antiretroviral (ARV) intervention (maternal, infant or no ARV regimen), and were closely 
followed during the period of exclusive breastfeeding from 0 to 24 weeks postpartum.  
Subjects and Methods 
Study population  
  The data for the current study are from the BAN study, whose design51 and primary 
intervention findings have been reported elsewhere.1,32,49 BAN was a randomized controlled 
trial of 2,369 mother-infant pairs conducted in Lilongwe, Malawi from April 2004 to 
February 2010. HIV 1-positive pregnant women (n=3572) were recruited from four antenatal 
clinics and screened for initial eligibility criteria including: age ≥ 14 years of age, CD4 count 
≥ 250 cells/µL (prior to 07/24/2006 CD4 cut off was ≥200 cells/µL in accordance with 
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Malawi Ministry of Health guidelines for HIV treatment), Hb ≥ 7 g/dL, no prior antiretroviral 
medication use, and no major pregnancy complications.1 From the screening visit to 1 week 
(wk) postpartum, all eligible mothers received daily iron-folic acid supplementation 
containing 200 mg ferrous sulfate and 5 mg folic acid according to the Malawi Ministry of 
Health care guidelines. At delivery, eligible women (n=2791) received maternal and infant 
single dose nevirapine peripartum as well as twice-daily zidovudine and lamivudine for 7 
days postpartum. Within 36 hours of delivery, mother-infant pairs had to present at the study 
site and meet secondary eligibility criteria for randomization including: infant birthweight ≥ 
2 kg, no severe congenital malformations, and no other conditions incompatible with survival 
or that would preclude the use of the study drugs. Of the 2382 mother-infant pairs who met 
secondary eligibility criteria, thirteen women declined further participation.  
  Mother-infant pairs (n=2369) were randomized using a permuted-block method to 
one of six treatment arms according to a two-arm nutritional and three-arm antiretroviral 
factorial design: maternal LNS/maternal ARV (mLNS-mARV), maternal LNS/infantARV 
(mLNS-iARV), maternal LNS (mLNS), maternal ARV (mARV), infant ARV (iARV), or 
control (C).49 Half of the mothers received a daily maternal LNS dose of 140 g providing 
estimated added energy and protein requirements of lactation and the recommended daily 
allowance of micronutrients including 15 mg of iron but excluding vitamin A (Supplemental 
Table 4.1).49 The LNS was intended to offset the energy and protein demands of lactation, 
and was instructed to be eaten in addition to regular foods. The LNS was produced by 
Nutriset (Malaunay, France) and contained: peanut butter, vegetable oil, dry skimmed milk 
powder, dry whey, sugar and micronutrients. Mothers in the maternal ARV arms (mLNS-
mARV & mARV) received a three-drug highly-active-regimen, while infants in the infant 
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ARV arms (mLNS-iARV & iARV) received daily oral nevirapine. On March 26, 2008, the 
data safety monitoring board halted enrollment in the no drug study arms (C & mLNS) 
because there was evidence that HIV transmission through breastmilk was higher in these 
groups.74 Mothers enrolled in these arms were allowed to change to the maternal or infant 
drug regimen for the remainder of exclusive breastfeeding.74 Further details of the ARV 
regimens are described elsewhere.49,74 Infants diagnosed by HIV-1 with polymerase chain 
reaction (PCR) within two wk of delivery (n=119) were disenrolled from the study, and 
mother-infant pairs were referred for care.1  
  In accordance with the World Health Organization prevention of maternal to child 
transmission of HIV (PMTCT) guidelines in development when the BAN study was 
designed,51,53 where exclusive breastfeeding for six months was recommended until 
acceptable, feasible, affordable, sustainable and safe (AFASS) conditions for replacement 
feeding are met, intensive counseling regarding exclusive breastfeeding was provided to 
BAN mothers. Mothers were instructed to exclusively breastfeed their infants for 24 wk and 
to wean between 24 and 28 wk.43 All participants were given 2 kg of maize per wk for family 
consumption to mitigate the effects of seasonal food shortages and to prevent sharing of 
maternal LNS. The World Food Program (WFP) provided food aid to all HIV-infected 
women in Lilongwe during a drought between February and August 2005. The aid consisted 
of a monthly ration of corn/soy flour and 1 liter of vitamin-A-fortified corn oil. An estimated 
260 mothers received the ration in lieu of the BAN maize package.32 Based on WHO 
recommendations, the BAN study initiated cotrimoxazole preventive therapy for infants 6-36 
wk of age in June 2006.52  
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  Informed consent was obtained from all participating mothers. The Malawi National 
Health Science Research Committee and the institutional review boards at University of 
North Carolina at Chapel Hill and the U.S. Centers for Disease Control and Prevention 
approved the study. 
Anthropometrics, study procedures and laboratory analyses 
  Participant visits were conducted at the BAN study clinic at Bwaila Hospital in 
Lilongwe. Mother-infant pairs were followed at birth and 1, 2, 4, 6, 8, 12, 18, 21, and 24 
weeks postpartum, which allows us to closely follow mothers and infants during when breast 
milk is the sole nutrition source for the infant. At birth and 2, 6, 12, 18, and 24 weeks 
maternal and infant Hb (g/dL) was measured using Beckman Coulter AcT Differential 
Analyzer or AcT 5-part Differential Analyzer (Beckman Coulter, Fullerton, CA). Infant HIV 
status was tested with Amplicor 1.5 DNA PCR at 0, 2, 12 and 28 wk. Positive postnatal HIV 
tests were confirmed with a specimen obtained at the following visit. Dried blood spots were 
tested using Gen-Probe Aptima HIV-1 RNA Qualitative assay to further refine the timing of 
infection in infants. At all visits, maternal and infant weight was measured using regularly 
calibrated Tanita digital electronic scales to the nearest 0.1 kg unit.Maternal height was 
measured with a wall-mounted stadiometer. Infant recumbent length was measured using a 
wooden length board made to UNICEF specifications.54 Nurses and nutrition assistants were 
trained in anthropometry and their methods were standardized.54  Maternal report of parity, 
marital status, and years of maternal education was obtained at the screening visit. Maternal 
report of infant’s exclusive breastfeeding status was obtained at 4, 8, 12, 18, 21 and 24 wk 
postpartum. 
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  Plasma was separated from red blood cells, aliquoted to 1 mL plastic storage tubes 
and stored at -70°C. To identify participants for inflammation and infection biomarker assays 
(n=537), samples were drawn from the LNS and no LNS groups where all multiple births 
and infants who became HIV positive at any time point were removed, and mother-infant 
pairs with anthropometry, and dietary data measurements were prioritized. Ferritin, 
transferrin receptors (TfR), and markers of inflammation [C-reactive protein (CRP) and α-1-
acid glycoprotein (AGP)] concentrations were measured at 2 or 6 and 24 wk postpartum 
using Cobas Integra 400 (Roche Diagnostics, Indianapolis, IN) in the subsample mother-
infant pairs. Initial biomarker measurements were obtained at 2 weeks in infants with 
sufficient plasma at that time; otherwise assays were conducted with plasma obtained at 6 
wk.  
Statistical analysis 
  This paper focuses on two groups of mother-infant pairs in BAN with Hb and iron 
measurements: mother-infant pairs with longitudinal Hb data (Longitudinal Hb sample), and 
a subset of these mother-infant pairs selected for additional biomarker analyses (MaMi 
subsample), who have additional measurements of iron status (TfR and ferritin), CRP and 
AGP.  Mother-infant pairs were excluded from analyses if the infant was a multiple (n=49), 
HIV-infected (n=58). Infants who were weaned early (n=277) were excluded from the 
longitudinal anlayiss up to the point of cessation of cessation of exclusive breastfeeding. 
STATA 12.0 (College Station, TX) was used for all statistical analyses.  
Longitudinal Hb sample 
  1926 mother-infant pairs had necessary data for the longitudinal Hb analyses: infant 
Hb at birth, concurrent maternal and infant Hb at subsequent visits, and birthweight. 
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Characteristics of the included mother-infant pairs in the longitudinal Hb sample (n=1926) 
were compared to characteristics of randomized mothers excluded from the analysis (n=443) 
to assess for similarity using t-tests for continuous, normally distributed variables, and 
nonparametric tests for skewed continuous variables. Compared to excluded randomized 
mothers, mothers in the longitudinal Hb sample were older (26.2 vs. 25.1 years, p<0.001), 
had lower prevalence of low CD4 (29% vs 35%, p<0.01), higher pregnancy Hb (10.8 vs. 10.6 
g/dL, p<0.001) had less anemia during pregnancy (52% vs. 60%, p=0.002), and fewer 
women were primiparous (12 vs. 16%, p=0.01). Infants in the longitudinal Hb sample had 
heavier birthweight (3.02 vs. 2.96 kg, p=0.001), higher birth length (48.2 vs. 47.9 cm, 
p<0.001), lower prevalence of low birth weight (6% vs. 12%, p<0.001), and were more likely 
to be in the ARV arm (38% vs. 29%, p<0.001).  
  To understand the influence of maternal anemia on infant iron status postpartum, we 
used linear regression to evaluate whether maternal anemia during pregnancy was associated 
with infant Hb at birth, adjusting for infant birthweight. We also evaluated whether maternal 
anemia during pregnancy (Hb <11 g/dL)75 was associated with infant Hb from 2 to 24 weeks 
using a longitudinal random effects model with a first order autoregressive disturbance term, 
adjusting for infant birthweight, birth Hb and rate of weight gain and age. Infant age was 
modeled with a spline with a knot at 9 weeks of age. 
  For the primary analysis in the longitudinal Hb sample, longitudinal random effects 
models were utilized to evaluate how maternal Hb related to concurrently measured infant 
Hb from 2 to 24 wk, modeled with first order autoregressive disturbance terms, adjusting for 
infant Hb at birth, infant gender, birthweight, and rate of weight gain since preceding visit. 
To capture the non-linear trend of Hb over time, infant age was modeled with a spline 
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containing one knot at 9 wks of age. Interactions of age with study interventions, rate of 
weight gain and infant Hb at birth were evaluated. The BAN study interventions were tested 
as potential confounders; however, none of the interventions had significant effects compared 
to mother-infant pairs in the control group (all p-values >0.20) and were not included in the 
final model.  
  In secondary analyses in the longitudinal Hb sample, we separately evaluated for 
intervention effects on maternal Hb and infant Hb. In the mothers, a longitudinal random 
effects model with a first order autoregressive disturbance terms was used to evaluate the 
effect of the maternal study interventions (mLNS-mARV, mARV, mLNS, control) on 
maternal Hb from 6 to 24 wk postpartum, adjusting for maternal Hb at 2 wk and time in 
weeks. Potential interactions with the study interventions and time were evaluated. In the 
infants, similar longitudinal random effects models were used to evaluate the effect of the six 
study interventions on infant Hb from 2 to 24 wk. Infant age was modeled a spline containing 
one knot at 9 wks of age. Potential interactions of study interventions, infant Hb at birth and 
rate of infant weight gain were also evaluated.  
MaMi Subsample 
   Plots and Shapiro-Wilk tests indicated that plasma ferritin, TfR, CRP, and AGP had a 
non-Gaussian distribution so these variables were log transformed. Characteristics were 
compared between mother-infant pairs included in the MaMi subsample (n=537) and 
excluded mother infant pairs (n=1832) to assess for similarity using t-tests for continuous, 
normally distributed variables, and nonparametric tests for skewed continuous variables. 
Compared to the excluded mother-infant pairs, mothers in the MaMi subsample were older 
(26.6 vs. 25.9 years, p=0.01), had lower BMI at delivery (23.3 vs. 23.7 kg/m2, p=0.02), and 
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were less likely to be married (90.5% vs. 93.3%, p=0.01) and infants had marginally higher 
birthweight (3.04 vs. 3.01 kg, p=0.06) and a lower prevalence of low birthweight (4.6% vs. 
8% p=0.01), and a larger proportion received the ARV intervention (41% vs. 35%, p=0.02).  
  Hb and ferritin are sensitive to infection and inflammation—Hb is lowered and 
ferritin is greatly increased.76 Though TfR is thought to be less sensitive to inflammation and 
infection,76 we observed associations of CRP and AGP with TfR, and therefore adjusted TfR 
for infection and inflammation. To remove the effects of inflammation from TfR, Hb and 
ferritin measurements, we used methods proposed by Thurnham and colleagues.77,78  We 
used previously used cutpoints to define elevated CRP (>5 mg/L) and AGP (>1 g/L) and 
stage of inflammation [healthy (normal CRP & AGP), incubation (elevated CRP), early 
convalescence (CRP & AGP elevated), late convalescence (elevated AGP)].78 We then 
determined correction factors for each inflammation group by dividing the median value of 
the healthy inflammation group by the median value of the incubation, early convalescence, 
and late convalescence groups.78 We then multiplied the measured Hb and iron status values 
by the group specific correction factor.78  
  In the primary MaMi subsample analyses, linear regression was used to evaluate how 
change in maternal iron status (Hb, ferritin and TfR) related to change in  infant iron status 
(Hb, ferritin, or TfR) from 2 (n=355) or 6 wk (n=167) to 24 wk (n=532), controlling for 
initial maternal and infant values, study ARV arm (mARV or iARV), infant birthweight, and 
whether the initial values were obtained at 2 or 6 wks postpartum. This approach allows us to 
theoretically evaluate whether maternal iron status relates to infant status during lactation 
independent initial maternal influence.  Maternal LNS was not included as a covariate in the 
models in order to isolate the effects of maternal serum status on infant status. We conducted 
 44 
 
a sensitivity analysis to evaluate how adjustment for infection and inflammation influenced 
our findings in the MaMi subsample mother-infant pairs. We used linear regression with 
unadjusted iron markers to evaluate the relationship between change in maternal iron marker 
on change in infant iron marker outcome, and observed associations similar to the 
inflammation adjusted models. In addition to these models, we used logistic regression to 
evaluate whether depleted maternal iron stores (ferritin <15 ug/L) at 2/6 weeks were 
associated with increased odds of depleted infant iron stores (ferritin <12 ug/L) at 2/6 weeks, 
adjusting for infant birthweight, ARV arm, when initial measurement was obtained and 
infant gender.  
   In secondary analyses in the MaMi subsample, we separately evaluated for 
intervention effects on maternal and infant iron status and Hb, adjusting for infant 
birthweight and gender. Interactions between LNS and ARV arms were also evaluated. We 
also conducted logistic regression models to determine if the study interventions were 
associated with increased odds of impaired infant iron status at 24 weeks, adjusting for initial 
iron status measurement, birthweight, timing of measurement and infant gender. Interactions 
between LNS and ARV intervention arms were also evaluated.  
Results  
 In general, mothers in both analyses were young, parous, married and had normal 
BMI at delivery, but more than half had anemia (Hb<11 g/dL)75 during pregnancy (Table 
4.1). Slightly more than half of the infants were male, few infants had low birthweight and 
infant Hb was high at birth.  
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Longitudinal Hb sample 
  From delivery to 24 wks postpartum, maternal Hb increased (Figure 4.1) and 
prevalence of maternal anemia (Hb <11 g/dL)75 decreased from about 50% to 31%. Mean 
infant Hb followed the typical pattern of decline from birth to 24 weeks, as fetal Hb is broken 
down79 (Figure 4.2). From 12-24 wk, prevalence of low infant Hb (<10.5 g/dL)79 increased 
from 43% to 50.3%. We observed that pregnancy anemia (Hb<11 g/dL)75 was associated 
with lower infant Hb at birth (β: 0.23 g/dL, p=0.01), adjusting for infant birthweight, but was 
not associated with infant Hb from 2 to 24 weeks in a longitudinal model (β: -0.08 g/dL, 
p=0.2).  
  The longitudinal model relating maternal and infant Hb over time indicates that 
higher maternal Hb predicts higher infant Hb over time (Supplemental Table 4.2) with 
significant associations between 6 and 18 wks (Figure 4.3). Female gender and higher 
birthweight were associated with higher infant Hb (p<0.001). Higher infant Hb at birth was 
associated with higher infant Hb over time, while faster weight gain—especially in younger 
infants—was associated with lower infant Hb over time.  
 Effects of the study interventions  
  LNS intervention effects were minimal on maternal Hb, while there were some 
adverse but not sustained effects of maternal ARV provision over time in both the mARV 
and mLNS-mARV groups (Supplemental Table 4.3).  Among mothers who received no 
ARVs, there were no differences in maternal Hb over time between women who received or 
did not receive LNS (all p-values >0.75). For mothers who received both LNS and ARVs 
(mLNS-mARV), predicted values from the longitudinal models indicate that maternal Hb 
was significantly lower at 6 and 12 wks postpartum (6 wk β: -0.32, p<0.001, 12 wk β: -0.20, 
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p<0.001); however, at 18 and 24 wks the negative effects were not sustained (all p-values 
>0.25). Similar effects were observed in mothers who received only ARVs (mARV), where 
maternal Hb was significantly lower at 6 and 12 wk postpartum (6 wk β: -0.22, p=0.001, 12 
wk β: -0.15, p=0.003), but again at 18 and 24 wks the negative effects were not sustained (all 
p-values >0.1). The longitudinal model of infant Hb shows no effects of the intervention 
arms on infant Hb (Supplemental Table 4.4).  
MaMi subsample 
  In the MaMi subsample, inflammation adjusted maternal Hb remained relatively 
stable from initial measurement to 24 wk, while maternal TfR declined (Table 4.2). Initially, 
prevalence of depleted maternal iron stores (adjusted ferritin <15 ug/L) was high, while 
fewer women had tissue iron depletion, denoted by elevated adjusted TfR (TfR >8.3 mg/L). 
By 24 weeks, about a third of women had depleted iron stores, but again fewer women had 
tissue iron depletion. Inflammation adjusted infant Hb declined from initial measurement to 
24 wk. Infant ferritin values declined markedly, while TfR increased from initial 
measurement to 24 wk. Few infants had abnormal initial adjusted measurements, but by 24 
wk many infants began to show signs of poor iron status. From initial measurement to 24 
weeks, prevalence of elevated CRP (>5 mg/L) and AGP (>1 g/L) declined in mothers and 
increased in infants.  
 Maternal TfR and Hb, but not ferritin, influenced infant values (Table 4.3). An 
increase in maternal TfR was associated with an increase in infant TfR, suggesting that 
worsening maternal iron status was related to worsening infant iron status. Similarly, an 
increase in maternal Hb was associated with an increase in infant Hb at 24 wk. In all models, 
initial infant values were the strongest predictor of change from the initial measurement. 
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Higher birthweight and female gender were strongly associated with lower TfR, but higher 
Hb and ferritin. In these models relating change in maternal value to change in infant value, 
maternal and infant ARV regimens had no effects on infant TfR, Hb or ferritin. In models 
relating maternal iron store depletion to odds of depleted infant iron stores, we observed that 
depleted maternal iron stores (ferritin <15 ug/L) at 2/6 weeks were not associated with 
depleted infant iron stores at both 2/6 and 24 weeks (ferritin <12 ug/L) (2/6 wk: OR: 2.23, 
p=0.32; 24 wk: 0.98, p=0.94). 
 Effects of the study interventions 
 mLNS was not related to maternal Hb, TfR, or Ferritin values at 2, 6, or 24 wk (all p-
values >0.1) (Table 4.4). mARV prophylaxis was associated with lower maternal Hb at 6 wk 
(p<0.001), but was unrelated to maternal ferritin (all p-values >0.05). mARV prophylaxis 
was associated with higher maternal TfR (suggestive of worsening iron status) at 6 and 24 
wks; however, the adverse ARV effect was reduced if the mother received LNS (Figure 4.4).  
  mLNS had no effects on infant Hb at any time (all p-values >0.1). mARV 
prophylaxis was associated with lower infant Hb at 2 wk, but not at later times. Similarly, 
iARV was associated with lower infant Hb only at 2 wk. We also evaluated whether the 
interventions were associated with odds of infant anemia at 24 weeks (Hb <10.5 g/dL), and 
observed a significant interaction between mLNS and iARV (Table 4.5); however, based on 
linear combinations of the mLNS, iARV and mLNS*iARV coefficients the mLNS coupled 
with iARV was not associated with increased odds of anemia (OR: 1.20, p=0.58).  
   mLNS had no effects on infant ferritin initially and was associated with lower infant 
ferritin at 24 weeks but not increased odds of infant iron store depletion (ferritin <12 ug/L)  
at 24 weeks. mARV or iARV prophylaxis had no effects on infant ferritin. mLNS was 
 48 
 
associated with higher infant TfR at 2 wk, but not at 6 or 24 weeks. At 2 wk, a significant 
interaction was observed between mLNS and mARV (p=0.07) as well as between mLNS and 
iARV (p=0.01) on infant TfR outcomes. Based on the linear combinations of mLNS, iARV 
and mLNX*iARV coefficients, the net effect of provision of mLNS along with iARV was 
not higher infant TfR (β: 0.17, p=0.15). On the other hand, based on the linear combinations 
of the mLNS, mARV and mLNS*mARV coefficients, the effect of mLNS provided with 
mARV was marginally higher infant TfR (β: 0.26, p=0.04). We tested whether the 
interventions were associated with increased odds of abnormal TfR (TfR>8.3), and observed 
no association. 
Discussion 
   In our study of HIV-infected Malawian mothers and their infants during exclusive 
breastfeeding, maternal Hb and TfR predicted infant values. More than half of mothers had 
anemia during pregnancy, which was associated with lower infant Hb at birth. This is 
important because the infant’s iron endowment at birth was related to subsequent risk of iron 
depletion postpartum. Initial maternal iron measurements indicate that despite routine 
supplementation during pregnancy, maternal iron stores were depleted in many women. 
Initial infant iron measurements suggest that the mechanisms to protect infant iron status 
were effective in the immediate postpartum period,71 since mean infant Hb at birth was 
within normal levels and few infants had depleted iron stores or high TfR initially. At 24 wk, 
however, infant iron status was poor, suggesting that initial infant stores at birth were 
insufficient for the period of exclusive breastfeeding and possibly that breastmilk iron levels 
may have been suboptimal. Interestingly, we observed no association between low maternal 
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ferritin at 2/6 weeks and low infant ferritin at 2/6 or 24 weeks; suggesting that breastmilk 
iron levels may have been protected in some mothers with impaired iron status. 
  In the longitudinal Hb mother-infant Hb models, higher maternal Hb predicts higher 
infant Hb between 6 and 18 wk. Similarly in the MaMi subsample where we corrected Hb 
measurements for infection and inflammation, larger increases in maternal Hb were 
associated with larger changes in infant Hb; providing further evidence that maternal Hb 
predicts infant Hb during exclusive breastfeeding.79 Conversely, larger increases maternal 
TfR predicted larger changes in infant TfR during breastfeeding, suggesting that worsening 
maternal iron status contributes to worsening infant status. Maternal iron stores must be 
depleted for tissue iron depletion to manifest as increased TfR levels, thus our observed 
association between maternal and infant TfR suggests that mothers with severely impaired 
iron status may have impaired breastmilk iron levels. We did not observe an association 
between maternal and infant ferritin, which has been previously observed.80 Infant iron stores 
at birth are regulated to be high in order to ensure adequate iron stores during breastfeeding; 
in our analysis this is apparent by the high infant ferritin values at 2 or 6 weeks. Given the 
underlying mechanisms to protect and maximize iron transfer to the fetus even with the 
presence of maternal anemia,81 and the many factors influence infant iron endowment at birth 
including gestational age,33 and timing of cord clamping82, the lack of an association between 
maternal and infant ferritin is not surprising and is further supported by the absence of an 
association between the initial maternal ferritin measurement and infant ferritin at 24 wk.  
 In the longitudinal Hb sample, the BAN study interventions—especially the ARV 
regimen—had some effect on maternal Hb. Though maternal LNS had 15 mg of iron, this 
may not have been enough to replete the iron stores of mothers with impaired iron status 
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postpartum. As such, our lack of LNS main effects was anticipated. Though we observed that 
ARVs provided with or without LNS had negative effects on maternal HB at 6 and 12 weeks, 
these effects were not sustained at later times. In the MaMi subsample, in contrast to our 
longitudinal model findings, we observed no interactions between mLNS and mARV on 
maternal Hb; but observed negative ARV effects on maternal Hb at 2 wk postpartum. 
Provision of maternal LNS mitigated some of the adverse effects of ARVs on maternal TfR 
values, indicating that LNS provision was protective for maternal iron status. 
  Even though we observed some effects of the BAN study interventions on maternal 
Hb, the study interventions had no influence on infant Hb values in the longitudinal Hb 
sample. This is consistent with a previous study in Turkish women, where maternal iron 
supplementation had little effect on milk iron content, the milk-maternal serum iron ratio or 
infant iron status;72,72 but women with anemia (Hb <11 g/dL) (who would have likely 
received the most benefit from the supplement) were excluded from the study.  
  In the MaMi subsample, we observed mixed effects of the study interventions on 
maternal and infant Hb and iron status. mLNS was not associated with maternal Hb, ferritin 
or TfR, while mARV provided with or without mLNS was associated with impaired maternal 
TfR. The study interventions were not associated with infant Hb at any time or with 
increased odds of anemia at 24 weeks. Though mLNS was associated with lower infant 
ferritin at 24 wk, it was not associated with increased odds of depleted infant iron stores 
(ferritin <12 ug/L) at 24 wk. We observed that provision of LNS coupled with maternal 
ARVs was associated with marginally higher infant TfR at 2 wk, but not at other times. 
However, the study interventions were not associated with increased odds of elevated TfR.  
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   This research has some limitations. First, we lacked measures of the acute phase 
response in the longitudinal Hb sample and were not able to adjust for inflammation and 
infection in this group. Because Hb is lowered in the presence of inflammation and infection, 
presence of illness or subclinical inflammation may have distorted our longitudinal Hb 
sample findings.  In our sensitivity analysis to evaluate how adjustment for infection and 
inflammation influenced our findings in the MaMi subsample mother-infant pairs, we 
observed associations similar to the inflammation adjusted models. This suggests that our 
longitudinal Hb model findings are likely not to be markedly affected by inflammation and 
infection. Second, we do not know whether mothers received and took iron supplements 
during pregnancy; however, by controlling for the mother’s initial measurement this may not 
have biased our findings.  
  In the MaMi subsample we have initial measurements of iron status and Hb at two 
time points due to insufficient plasma availability at 2 weeks postpartum. During this time 
period, infant iron status, particularly Hb, changes dramatically. We utilized a dummy 
variable for time of measurement in our primary models in order to retain our full MaMi 
subsample for the change analyses, which was influential in the TfR and Hb models. To 
evaluate intervention effects, we used linear regression at each time point and may not have 
had sufficient power to detect LNS effects with initial measurements, as the sample at 2 
weeks may have been too small to detect associations, as the mothers in the mLNS group 
only had 2 weeks of LNS consumption.   
  In the longitudinal Hb sample, we excluded about 19% of randomized mother-infant 
pairs from our longitudinal analysis if they did not have measurements required for inclusion 
in the analysis (birthweight, birth Hb, and concurrently measured mother-infant Hb) (n= 
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217), or were multiple births (n=49), HIV-infected in first 2 wk (n=119) or HIV-infected 
from 2 to 24 wk (n=58). Infants weaned early were censored when maternal reports indicated 
that the infant was no longer exclusively breastfed (n=277). Compared to infants included in 
the longitudinal Hb sample, worse off infants and mothers were excluded or lost-to-follow 
up. Similarly, mother-infant pairs in the MaMi subsample were healthier than randomized 
infants. As such, we may have underestimated the observed relationships between maternal 
and infant Hb and iron status. 
  This study also has many strengths. This is the first study to characterize the 
relationship between maternal and infant iron status using multiple iron measures during 
exclusive breastfeeding.  In these analyses, we controlled for the infant’s initial 
measurement; therefore we are theoretically observing the effects of breastmilk iron, as 
breastmilk was the sole source of nutrition for BAN infants during this time. Applying a 
dyadic modeling framework is an innovative approach to examine these mother-infant iron 
status relationships. Supporting this approach are our detailed exclusive breastfeeding data, 
which allowed us to exclude weaned and mixed fed infants from our analyses, as the mother 
was no longer the sole source of nutrition for her growing infant and infants who potentially 
received other sources of iron in complementary foods were also excluded. Moreover, our 
analysis focused on the early postpartum period, a period where infant iron status is not well 
characterized, and adds to our understanding of iron status dynamics during this time. 
Finally, understanding these relationships is especially important in the context of HIV to 
guide future interventions and programs to promote maternal and infant health and to 
optimize maternal and infant iron status.  
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  The LNS and ARV interventions had few sustained effects on maternal and infant Hb 
and iron status over time in the longitudinal Hb sample.  In the MaMi subsample, we 
observed that the mLNS and the mLNS-mARV interventions were associated with impaired 
TfR and ferritin values, respectively; however, they were not associated with increased odds 
of abnormal values. The current WHO recommendations for infant feeding in the context of 
HIV is forsix months of exclusive breastfeeding followed by introduction of appropriate 
complementary foods with continued breastfeeding for 12 months, along with provision of 
ARV prophylaxis to the mother or infant up to 1 wk after cessation of breastfeeding. Given 
these recommendations along with the high nutritional demands of lactation and HIV, 
providing LNS with only 15 mg of iron along with ARVs to HIV-infected lactating women 
may have little clinical significance for maternal and infant iron status, but LNS still may be 
valuable to support breastfeeding in HIV-infected mother in resource poor settings.49 LNS 
may be particularly advantageous in places with corn-based staple foods, such as nsima in 
Malawi, since phytates present in corn may inhibit iron absorption and increase likelihood of 
poor iron status.  
  Given the observed association between maternal and infant Hb and TfR, and the 
strong sustained effects of infant’s birth Hb in the longitudinal Hb sample and initial iron 
status measurements in the MaMi subsample on later status, optimizing maternal iron status 
is important for reducing risk of iron depletion in infants. Further research to understand how 
iron status markers relate to breastmilk iron levels appear warranted. Moreover, further 
research to understand how ARVs affect maternal and infant iron status from 6 to 12 months 
is needed. 
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Table 4.1 Characteristics of mother-infant dyads in both analysis samples 
 Longitudinal Hb Sample 
n=1926 
MaMi Subsample 
n=5191 
MOTHERS   
Age (y)2 26.2 ± 5.0 26.6 ± 5.2 
Height (cm)2 156.88 ± 5.52 156.57 ± 5.40 
BMI at 2 wk postpartum (kg/m2)2 23.59 ± 3.03 22.85 ± 2.98 
CD4 (cells/µL) 2,3 480.97 ± 197.92 482.63 ± 221.68 
CD4 < 350 cells/µL (%) 28.6 30.1 
Hb (g/dL) 2,3 10.8 ± 1.22 10.80 ± 1.18 
Anemia (%)3 52.0 53.8 
Primaparous (%) 11.6 10.3 
Married (%) 92.3 90.2 
Education (%) 35.0 36.8 
   
INFANTS   
Female (%) 49.3 47.6 
Birthweight (kg)2 3.03 ± 0.40 3.05 ± 0.39 
Low birthweight (%) 6.2 4.6 
Birth length (cm)2 48.22 ± 1.94 48.23 ± 1.96 
Hb at birth (g/dL)2 17.44 ± 2.02 17.34 ± 2.09 
   
STUDY INTERVENTION (%)4  
mLNS-mARV 17.7 16.8 
mARV 17.6 15.8 
mLNS-iARV 19.2 20.0 
iARV 18.5 20.4 
mLNS 13.2 14.5 
C 13.9 12.5 
1Though 537 mother-infant pairs were included in the MaMi subsample, 18 of these pairs 
were missing mother or infant inflammatory marker measurements and were not included in 
this analysis 
2Mean ± SD  
3Measured during pregnancy, Anemia defined as Hb <11 g/dL75 
4Study intervention: maternal LNS/maternal ARV (mLNS-mARV), maternal 
LNS/infantARV (mLNS-iARV), maternal LNS (mLNS), maternal ARV (mARV), infant 
ARV (iARV), or control (C) 
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Table 4.2 Infection, Hb and inflammation adjusted and unadjusted markers of iron status of MaMi subsample mother-infant 
dyads1 
Initial measurement 24 week 
2 week 6 week 
Unadjusted Adjusted2 Unadjusted Adjusted2 Unadjusted Adjusted2 
MOTHER 
Hb(g/dL)3 11.9 ± 1.6 (365) 12.6 ± 1.6 (360) 12.0 ± 1.4 (170) 12.2 ± 1.3 (170) 12.4 ± 1.2 (535) 12.6 ± 1.2 (534) 
Adverse event 
(%)4 11.2 6.4 7.7 6.47 2.99 1.5 
Low (%)4 47.4 35.28 42.35 38.82 34.77 29.59 
 
Ferritin (ng/mL)3 46.3 ± 55.2 (367) 29.98 ± 37.26 (362) 42.83 ± 65.27 (170) 43.09 ± 63.69 (170) 34.65 ± 47.82 (537) 32.38 ± 43.08 (536) 
Deficient(%)4 23.98 39.23 33.53 32.35 31.28 33.4 
 
TfR (mg/L)3 5.68 ± 2.80 (367) 5.69 ± 2.82 (362) 5.98 ± 3.70 (170) 5.67 ± 3.50 (170) 5.09 ± 2.42 (536) 4.86 ± 2.27 (535) 
Deficient(%)4 13.08 12.71 18.24 15.88 8.77 6.92 
 
Elevated inflammatory markers 
CRP >5 mg/L (%) 42.9 - 22.4 - 16.4 - 
AGP >1 g/L (%) 76.8 - 47.7 - 33.5 - 
 
INFANT 
Hb (g/dL)3 14.25 ±1.79 (357) 14.30 ± 1.78 (351) 11.05 ± 1.30 (165) 11.14 ± 1.28 (163) 10.39 ± 1.11 (530) 10.47 ± 1.10 (526) 
Adverse event(%)5 26.89 26.21 10.91 9.82 56.98 54.37 
Low(%)5 - - - - 71.7 69.39 
 
Ferritin (ng/mL)3 479.5 ± 354.3 (359) 462.7 ± 338.7 (359) 
322.11 ± 238.53 
(168) 
314.67 ± 228.92 
(167) 40.02  ± 94.34 (537) 42.34 ± 102.80 (533) 
Deficient(%)5 1.95 1.39 6.55 2.99 32.96 30.96 
 
TfR(mg/L)3 3.56 ± 1.94 (360) 3.53 ± 1.90 (360) 3.55 ± 2.13 (165) 3.35 ± 1.91 (165) 6.88 ± 3.47 (532) 6.64 ± 3.33 (531) 
Deficient(%)5 1.67 1.67 3.64 3.03 24.44 21.85 
 
Elevated inflammatory markers 
CRP >5 mg/L (%) 8.9 - 16.2 - 28.5 - 
AGP >1 g/L (%) 8.6 - 16.1 - 47.0 - 
1Hb, serum hemoglobin; TfR, plasma soluble transferrin receptor; CRP, plasma C-reactive protein; AGP, plasma α1-acid glycoprotein. 
2Adjusted for inflammation by using group specific correction factors estimated from ratios of medians for the various iron indicators77 
3Values are Mean ± SD (n) 
4Adverse event for maternal Hb was defined as <10.0 g/dL,83low <12 g/dL,37abnormal ferritin <15 ng/mL, abnormal TfR>8.3 mg/L 
5Adverse event for infant Hb is <13 g/dL from 1-21 d, <10.5 g/dL 22-35 d, <9.4g/dL from 36-56 d, <10.9 g/dL ≥56 d.83 Low infant Hb was defined as <10.5 g/dL.79 
Abnormal infant TfR >8.3 mg/L and ferritin <12 ng/mL.  
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Table 4.3 Linear regression models showing the effects of change in maternal iron status on change in infant iron status 
outcomes (log transferrin receptors, hemoglobin, log ferritin) from 2/6 to 24 weeks, adjusted and unadjusted for 
inflammation1,2 
  Log TfR (n=513) Hb (n=496) Log Ferritin (n=518) 
  β 95% CI p-value β 95% CI p-value β 95% CI p-value 
Inflammation Adjusted  
Change in maternal 
value 0.18 [0.06, 0.29] <0.001 0.13 [0.03, 0.23] 0.01 0.06 [-0.06, 0.17] 0.34 
Infant initial value 
-0.66 [-0.72, -0.60] <0.001 -0.89 [-0.94, -0.83] <0.001 -0.92 [-1.01, -0.83] <0.001 
Maternal initial value 0.23 [0.14, 0.33] <0.001 0.1 [0.02, 0.18] 0.02 0.03 [-0.08, 0.14] 0.61 
Infant birthweight 
-0.23 [-0.32, -0.14] <0.001 0.46 [0.22, 0.70] <0.001 0.34 [0.13, 0.56] <0.001 
mARV3 
-0.01 [-0.10, -0.09] 0.85 0.1 [-0.14, 0.34] 0.41 0.14 [-0.08, 0.35] 0.22 
iARV3 0.03 [-0.05, 0.12] 0.43 -0.11 [-0.35, 0.12] 0.34 -0.1 [-0.30, 0.11] 0.35 
Initial measure at 6 wk 0.21 [0.13, 0.28] <0.001 0.32 [0.05, 0.59] 0.02 0.13 [-0.06, 0.31] 0.18 
Female gender -0.19 [-0.26, -0.12] <0.001 0.15 [-0.04, 0.34] 0.11 0.45 [0.28, 0.62] <0.001 
 
Inflammation unadjusted  
Change in maternal 
value 0.18 [0.06, 0.29] 0.002 0.13 [-.03, 0.23] 0.01 0.06 [-1.01, -0.83] 0.34 
Infant initial value 
-0.66 [-0.72, -0.60] <0.001 -0.89 [-0.94, -0.83] <0.001 -0.92 [-0.08, 0.14] <0.001 
Maternal initial value 0.23 [0.14, 0.33] <0.001 0.10 [0.02, 0.18] 0.02 0.03 [0.13, 0.56] 0.61 
Infant birthweight 
-0.23 [-0.32, -0.14] <0.001 0.46 [0.22, 0.70] <0.001 0.34 [-0.08, 0.35] 0.00 
mARV3 
-0.01 [-0.10, 0.09] 0.85 0.10 [-0.14, 0.34] 0.41 0.14 [-0.30, 0.11] 0.22 
iARV3 0.03 [-0.05, 0.12] 0.43 -0.11 [-0.35, 0.12] 0.34 -0.10 [-0.06, 0.31] 0.35 
Initial measure at 6 wk 0.21 [0.13, 0.28] <0.001 0.32 [-0.05, 0.59] 0.02 0.13 [0.28, 0.62] 0.18 
Female gender 
-0.19 [-0.26,-0.12] <0.001 0.15 [-0.04, 0.34] 0.11 0.45 [-0.19, 1.68] <0.001 
1LNS arm was not included in the model to isolate the effects of maternal iron status independent of study supplement 
2Hb, serum hemoglobin; TfR, plasma soluble transferrin receptor; CRP, plasma C-reactive protein; AGP, plasma α1-acid glycoprotein. 
3mARV(maternal ARV), iARV (infant ARV) 
 
 
  
 
 
 
 
 
 
 
 56
 
 
  
 
Table 4.4 Associations between the BAN study interventions and maternal and infant Hb, TfR and ferritin outcomes in MaMi 
subsample1 
  Initial measurement   24 weeks 
  2 weeks    6 weeks      
 Coef. 95% CI p-value  Coef. 95% CI p-value  Coef. 95% CI p-value 
MOTHER            
Hb (g/dL)  n=360    n=170    n=534  
mLNS -0.03 [-0.37, 0.30] 0.85  -0.03 [-0.43, 0.36] 0.88  -0.01 [-0.20, 0.19] 0.94 
mARV -0.01 [-0.38, 0.35] 0.94  -0.72 [-1.13, -0.32] 0.001  -0.02 [-0.23, 0.19] 0.86 
 
           
Log Ferritin (ng/mL)  n=362    n=170    n=536  
mLNS -0.06 [-0.25, 0.13] 0.53  0.09 [-0.20, 0.37] 0.55  0.04 [-0.10, 0.18] 0.53 
mARV 0.17 [-0.03, 0.38] 0.10  -0.25 [-0.55, 0.04] 0.09  -0.06 [-0.21, 0.09] 0.45 
            
Log TfR (mg/L)  n=362    n=170    n=535  
mLNS 0.03 [-0.08, 0.14] 0.61  0.15 [-0.04, 0.35] 0.11  0.02 [-0.06, 0.10] 0.64 
mARV -0.11 [-0.25, 0.04] 0.15  0.36 [0.15, 0.57] 0.001  0.25 [0.15, 0.35] <0.001 
mLNS*mARV 0.03 [-0.18, 0.23] 0.81  -0.27 [-0.58, 0.03] 0.08  -0.11 [-0.26, 0.03] 0.13 
 
           
INFANT            
Hb (g/dL)  n=351    n=163    n=526  
Birthweight 0.23 [-0.26, 0.72] 0.35  0.60 [0.10, 1.10] 0.02  0.58 [0.34, 0.82] <0.001 
Female 0.35 [-0.03, 0.73] 0.07  0.31 [-0.10, 0.72] 0.13  0.17 [-0.02, 0.36] 0.07 
mLNS -0.25 [-0.62, 0.13] 0.20  -0.05 [-0.45, 0.34] 0.79  -0.13 [-0.32, 0.06] 0.18 
mARV -0.47 [-0.94, 0.003] 0.05  -0.07 [-0.63, 0.49] 0.80  0.02 [-0.22, 0.26] 0.89 
iARV -0.73 [-1.17, -0.28] 0.001  -0.36 [-0.91, 0.19] 0.20  -0.21 [-0.44, 0.02] 0.07 
            
Log Ferritin (ng/mL)  n=359    n=167    n=533  
Birthweight 0.19 [-0.05, 0.43] 0.12  0.17 [-0.24, 0.59] 0.41  0.36 [0.15, 0.57] 0.001 
Female 0.16 [-0.02, 0.34] 0.08  0.24 [-0.10, 0.57] 0.16  0.47 [0.31, 0.64] <0.001 
mLNS -0.12 [-0.30, 0.06] 0.20  -0.27 [-0.60, 0.05] 0.10  -0.21 [-0.37, -0.05] 0.01 
mARV 0.03 [-0.20, 0.26] 0.79  0.15 [-0.31, 0.61] 0.52  0.17 [-0.04, 0.38] 0.11 
iARV -0.04 [-0.25, 0.17] 0.71  0.26 [-0.20, 0.71] 0.27  -0.08 [-0.28, 0.12] 0.42 
            
Log TfR (mg/L)  n=360    n=165    n=531  
Birthweight  0.02 [-0.15, 0.20] 0.78  -0.14 [-0.32, 0.05] 0.15  -0.26 [-0.36, -0.15] <0.001 
Female -0.17 [-0.31, -0.03] 0.01  -0.12 [-0.27, 0.03] 0.12  -0.26 [-0.34, -0.18] <0.001 
mLNS 0.35 [0.11, 0.59] 0.004  0.05 [-0.10, 0.19] 0.53  -0.01 [-0.09, 0.07] 0.87 
mARV 0.23 [-0.02, 0.48] 0.08  0.04 [-0.17, 0.25] 0.70  0.05 [-0.05, 0.16] 0.33 
iARV 0.23 [-0.002, 0.47] 0.05  -0.03 [-0.24, 0.17] 0.76  0.05 [-0.05, 0.15] 0.36 
mLNS*mARV -0.31 [-0.65, 0.03] 0.07   -    -  
mLNS*iARV -0.42 [-0.74, -0.10] 0.01   -    -  
1Linear regression models tested for intervention associations with maternal and infant Hb and iron status outcomes. We tested for significant interactions 
between mLNS and mARV/iARV, if significant (p<0.1) the interaction term was retained in the model. Hb, hemoglobin; TfR, transferrin receptors; BAN, 
Breastfeeding Antiretroviral and Nutrition; MaMi, Malawi Mothers and Infants; mLNS, maternal LNS; mARV, maternal ARV; iARV, infant ARV. 
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Table 4.5 Associations between study interventions and odds of impaired infant iron status at 24 weeks in the MaMi 
subsample1 
High TfR Low Hb Low  ferritin 
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Initial measurement 9.16 [4.77, 17.59] <0.001 0.79 [0.70, 0.89] <0.001 0.64 [0.52, 0.79] <0.001 
Birthweight 0.32 [0.17, 0.62] <0.001 0.30 [0.18, 0.50] <0.001 0.40 [0.24, 0.69] <0.001 
mARV 1.25 [0.66, 2.36] 0.49 0.97 [0.49, 1.94] 0.94 0.79 [0.47, 1.33] 0.37 
iarV 1.50 [0.82, 2.75] 0.19 1.50 [0.77, 2.91] 0.24 1.29 [0.80, 2.08] 0.30 
mLNS 0.95 [0.60, 1.52] 0.84 1.78 [0.87, 3.63] 0.11 1.18 [0.80, 1.75] 0.40 
mLNS*mARV - 0.52 [0.20, 1.35] 0.18 - 
mLNS*iARV - 0.45 [0.18, 1.14] 0.09 - 
Initial measurement at 6 wk  3.50 [2.12, 5.75] <0.001 0.37 [0.21, 0.64] <0.001 0.59 [0.38, 0.92] 0.02 
Female 0.53 [0.32, 0.86] 0.01 0.67 [0.46, 0.98] 0.04 0.44 [0.29, 0.66] <0.001 
1Logistic regression models tested for intervention effects with impaired infant iron status outcomes. We tested for significant interactions between mLNS and 
mARV/iARV, if significant (p<0.1) the interaction term was retained in the model. 
2Impaired infant iron status:Low Hb <10.5 g/dL79 & low ferritin <12 ng/mL, high TfR >8.3. Hb, hemoglobin; TfR, transferrin receptors; BAN, Breastfeeding 
Antiretroviral and Nutrition; MaMi, Malawi Mothers and Infants; mLNS, maternal LNS; mARV, maternal ARV; iARV, infant ARV.58 
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Figure 4.1 Mean maternal hemoglobin (g/dL) values according to BAN study arm from 
birth to 24 weeks 
Data among BAN mothers in the longitudinal Hb sample with at least one concurrent mother 
and infant Hb measurement (n=623 in the C arm; n=338 in the mARV arm; n=624 in the 
mLNS arm; n=341 in the maternal ARV-LNS arm). mARVLNS, maternal LNS/maternal 
ARV; mLNS, maternal LNS; mARV, maternal ARV; C, control; BAN, Breastfeeding, 
Antiretroviral and Nutrition; LNS, lipid-based nutrient supplement; ARV, antiretroviral drug. 
 
 
 
10
10.5
11
11.5
12
12.5
13
13.5
14
14.5
15
0 2 4 6 8 10 12 14 16 18 20 22 24
H
e
m
o
g
lo
b
in
 (
g
/d
L)
Weeks
C mARV mLNS mARVLNS
 60 
 
  
Figure 4.2 Infant hemoglobin (g/dL) values according to BAN study arm from birth to 
24 weeks 
Data among BAN infants in the longitudinal Hb sample with at least one concurrent mother 
and infant Hb measurement (n=341 in the mLNS-mARV arm; n=338 in the mARV arm; 
n=369 in the mLNS-iARV arm; n=356 in the iARV arm; n=255 in the mLNS arm; n=267 in 
the C arm). mLNS-mARV, maternal LNS/maternal ARV; mARV, maternal ARV; mLNS-
iARV, maternal LNS/infant ARV; iARV, infant ARV; mLNS, maternal LNS; C, control. 
BAN, Breastfeeding, Antiretroviral and Nutrition; LNS, lipid-based nutrient supplement; 
ARV, antiretroviral drug. 
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Figure 4.3 Predicted infant Hb coefficients (β ± 95% Confidence Interval) for each age 
in BAN infants 
Predicted Hb values (g/dL) from a longitudinal random effects model model relating 
maternal Hb to infant Hb containing a spline with a knot at 9 weeks to capture the shape of 
infant Hb over time. Predicted values represent at each age the linear combination of the 
maternal Hb coefficient and the maternal Hb interactions with age. The model also contained 
infant age (p<0.001), and infant age after 9 weeks (p<0.001), female gender (p<0.001), infant 
birthweight (p<0.001), infant Hb at birth (p<0.001), and rate of weight gain since previous 
visit (p<0.001). Interaction terms with age and age >9 wk included: infant birth Hb (p<0.001) 
rate of weight gain since previous visit (p<0.001). Data from HIV-negative infants and their 
mothers with at least one concurrent mother infant Hb measurement and birth Hb were 
included until 24 weeks or cessation of exclusive breastfeeding: n=341 in the mLNS-mARV 
arm; n=338 in the mARV arm; n=369 in the mLNS-iARV arm; n=356 in the iARV arm; 
n=255 in the mLNS arm; n=267 in the C arm. BAN, Breastfeeding, Antiretroviral and 
Nutrition; mLNS-mARV, maternal LNS/maternal ARV; mARV, maternal ARV; mLNS-
iARV, maternal LNS/infant ARV; iARV, infant ARV; mLNS, maternal LNS; C, control. Hb, 
Hemoglobin; BAN, Breastfeeding Antiretoviral and Nutrition; LNS, lipid-based nutrient 
supplement; ARV, antiretroviral intervention.   
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Figure 4.4 Effects of LNS among women in the MaMi subsample who recieved ARVs 
Maternal ARV treatment was associated with higher maternal log TfR (suggestive of iron 
deficiency) at 6 and 24 weeks; but this adverse ARV effect was reduced if mothers also 
received LNS. Predicted maternal log TfR values (mg/L) in mothers in the ARV intervention 
arms from linear model of BAN study interventions maternal Hb outcomes. ARV, 
antiretroviral; TfR, transferrin receptors; BAN, Breastfeeding, Antiretroviral and Nutrition. 
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Supplemental Table 4.1 Composition of daily ration (140 g) of lipid-based nutrient 
supplements given to BAN Study mothers1 
Component Provides 
Energy 746 kcal 
Protein 20.8 g 
Lipids 49.6 g 
Iron 15 mg 
Zinc 19 mg 
Phosphorus 1200 mg 
Selenium 75 µg 
B1 (thiamin) 1.6 mg 
B2 (riboflavin) 1.8 mg 
B3 (niacin) 20 mg equiv 
B6 (pyridoxine) 2.2 mg 
B12 (cyanocobalamine) 2.6 µg 
C (ascorbic acid) 100 mg 
E (α-tocopherol) 12 mg 
Folic acid 300 µg 
Iodine 400 µg 
Potassium 1144 mg 
Magnesium 124 mg 
Copper 0.30 mg 
Calcium 588 mg 
1The supplement was produced by Nutriset in Malaunay, France (www.nutriset.com) from 
peanut butter, vegetable fat, dried skimmed milk, dry whey, dextrinmaltose sugar and a 
mineral and vitamin complex. BAN, Breastfeeding Antiretroviral, and Nutrition  
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Supplemental Table 4.2 Longitudinal random effects model with first order 
autoregressive disturbance terms showing the associations between maternal Hb and  
infant Hb (g/dL) in 1926 BAN mother-infant pairs in the longitudinal Hb sample1 
 Coef. 95% CI p-value 
Mom Hb -0.04 [-0.09,0.01] 0.15 
Mom Hb*Age 0.01 [0.00,0.02] 0.002 
Mom Hb*Age spline -0.02 [-0.03,-0.01] 0.004 
Age  0.57 [0.43,0.71] <0.001 
Age spline -0.67 [-0.86,-0.49] <0.001 
Female 0.25 [0.13,0.38] <0.001 
Birthweight (kg) 0.49 [0.33,0.65] <0.001 
Infant birth Hb 0.73 [0.68,0.77] <0.001 
Infant birth Hb*Age 0.07 [0.06,0.08] <0.001 
Infant birth Hb*Age spline -0.07 [-0.07,-0.06] <0.001 
Rate of weight gain (kg/wk) -0.27 [-0.40,-0.14] <0.001 
Rate of weight gain*Age spline 0.34 [0.31,0.38] <0.001 
Rate of weight gain*Age spline -0.15 [-0.17,-0.12] <0.001 
Intercept 1.70 [0.59,2.82] 0.003 
1The longitudinal model contained a spline with a knot at 9 weeks to capture the shape of 
infant Hb over time. BAN study interventions were tested as a potential confounders and 
effect-measure-modifiers, but were not included in the final model. Data from HIV-negative 
infants and their mothers with at least one concurrent mother infant Hb measurement and 
birth Hb measurement were included until 24 weeks or cessation of exclusive breastfeeding: 
n=341 in the mLNS-mARV arm; n=338 in the mARV arm; n=369 in the mLNS-iARV arm; 
n=356 in the iARV arm; n=255 in the mLNS arm; n=267 in the C arm. BAN, Breastfeeding, 
Antiretroviral and Nutrition; mLNS-mARV, maternal LNS/maternal ARV; mARV, maternal 
ARV; mLNS-iARV, maternal LNS/infant ARV; iARV, infant ARV; mLNS, maternal LNS; 
C, control. Hb, Hemoglobin; BAN, Breastfeeding Antiretoviral and Nutrition; LNS, lipid-
based nutrient supplement; ARV, antiretroviral intervention.   
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Supplemental Table 4.3 Longitudinal random effects model with first order 
autoregressive disturbance terms showing the associations between BAN study 
intervention arm and maternal Hb outcomes (g/dL) in 1765 BAN mothers from 6 to 24 
weeks1 
 Coef. 95% CI p-value 
Mom Hb at 2 week 0.90 [0.88,0.93] <0.001 
mLNS-mARV -0.41 [-0.54,-0.27] <0.001 
mARV -0.23 [-0.37,-0.09] 0.00 
mLNS 0.00 [-0.11,0.12] 0.98 
mLNS-mARV*Week 0.02 [0.01,0.03] <0.001 
mLNS*Week 0.00 [-0.00,0.01] 0.62 
mARV*Week 0.01 [0.00,0.02] 0.00 
Week 0.01 [0.01,0.02] <0.001 
Intercept 1.08 [0.77,1.40] <0.001 
1A Wald test for the study intervention interactions with weeks indicated a significant effect 
of the interventions over time (Χ2(3) =  42.08, p<0.001). Data from BAN mothers with at 
least one maternal Hb measurement after two weeks postpartum were included: n=569 in C; 
n=315 in mARV; n=573 in mLNS; n=308 in mLNS-mARV. mARV-LNS, maternal 
LNS/maternal ARV; mLNS, maternal LNS; mARV, maternal ARV; C, control; BAN, 
Breastfeeding, Antiretroviral and Nutrition; LNS, lipid-based nutrient supplement; ARV, 
antiretroviral drug.  
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Supplemental Table 4.4 Longitudinal random effects model with first order 
autoregressive disturbance terms showing the associations between the BAN study 
interventions and infant Hb (g/dL) outcomes in 1926 BAN infants1 
Coef. 95% CI p-value 
Infant birth Hb 0.73 [0.68,0.77] <0.001 
Birthweight 0.49 [0.34,0.65] <0.001 
Female 0.26 [0.13,0.38] <0.001 
Rate of wt gain/month -0.28 [-0.40,-0.15] <0.001 
Age 0.72 [0.61,0.83] <0.001 
Age spline -0.86 [-1.00,-0.72] <0.001 
Rate*Age spline 0.34 [0.31,0.38] <0.001 
Rate*Age  -0.15 [-0.17,-0.12] <0.001 
Birth Hb*Age spline 0.07 [0.06,0.08] <0.001 
Birth Hb* Age -0.07 [-0.07,-0.06] <0.001 
mLNS-mARV -0.09 [-0.42,0.23] 0.57 
mARV -0.11 [-0.43,0.21] 0.49 
mLNS-iARV -0.18 [-0.50,0.14] 0.26 
iARV -0.20 [-0.52,0.12] 0.22 
mLNS -0.24 [-0.59,0.11] 0.18 
mLNS-mARV*Age 0.01 [-0.03,0.06] 0.53 
mARV*Age 0.01 [-0.03,0.05] 0.55 
mLNS-iARV*Age -0.02 [-0.06,0.02] 0.43 
iARV*Age -0.01 [-0.05,0.03] 0.76 
mLNS*Age 0.02 [-0.02,0.07] 0.32 
mLNS-mARV*Age spline -0.01 [-0.07,0.04] 0.64 
mARV*Age spline -0.01 [-0.06,0.04] 0.65 
mLNS-iARV*Age spline 0.04 [-0.01,0.09] 0.11 
iARV*Age spline 0.02 [-0.03,0.08] 0.38 
mLNS*Age spline -0.03 [-0.09,0.03] 0.28 
Intercept 1.40 [0.40,2.40] 0.01 
1The longitudinal model contained a spline with a knot at 9 weeks to capture the shape of 
infant Hb over time. Data from HIV-negative BAN infants with at least one Hb measurement 
after birth were included until 24 weeks or cessation of exclusive breastfeeding: n=341 in the 
mLNS-mARV arm; n=338 in the mARV arm; n=369 in the mLNS-iARV arm; n=356 in the 
iARV arm; n=255 in the mLNS arm; n=267 in the C arm. BAN, Breastfeeding, Antiretroviral 
and Nutrition; mLNS-mARV, maternal LNS/maternal ARV; mARV, maternal ARV; mLNS-
iARV, maternal LNS/infant ARV; iARV, infant ARV; mLNS, maternal LNS; C, control. Hb, 
Hemoglobin; BAN, Breastfeeding Antiretoviral and Nutrition; LNS, lipid-based nutrient 
supplement; ARV, antiretroviral intervention.   
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Chapter 5: Synthesis 
 
Overview of findings 
 This research examined the nutritional interrelationships of the mother-infant dyad in 
HIV-infected Malawian women and their exclusively breastfed infants. We used data from a 
large clinical trial, the Breastfeeding, Antiretrovirals and Nutrition (BAN) Study 
(www.thebanstudy.org), which was based in Lilongwe, Malawi, and a sub-study of BAN, the 
Malawi Mothers and Infants (MaMi) Study. Data for this study was obtained during the 
screening visit for BAN, and at BAN visits from birth to 24 weeks postpartum, 
corresponding with exclusive breastfeeding. Data for the MaMi study was obtained at 2 or 6 
and 24 weeks. These datasets provided a unique opportunity to understand the nutritional 
interrelationships of the mother-infant dyad during exclusive breastfeeding. We chose to 
examine two important markers of maternal and infant nutritional status during this time: 
anthropometry and iron status. First, we explored how maternal anthropometry patterns 
related to infant growth. Second, we used longitudinal modeling to understand how maternal 
and infant Hb were related over time. Finally, we used linear models to understand how 
maternal and infant Hb and iron status, measured by transferrin receptors (TfR) and ferritin, 
were related, after accounting for inflammation and infection. The following section provides 
a summary and synthesis of our primary findings. 
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Maternal weight loss is associated with reduced length and weight gain in daughters of 
HIV-infected Malawian women 
 
  We aimed to understand how maternal weight changes during lactation translated into 
infant growth. We hypothesized that infants of mothers losing weight would have impaired 
growth if the mother had limited nutrient stores to mobilize. We used linear regression 
models to relate maternal weight loss to infant weight and length gain, adjusting for infant 
anthropometry at birth, maternal BMI, and covariates. We interacted maternal BMI with 
dichotomous weight loss to determine whether the effects of weight loss varied by initial 
energy stores.  
 We found that maternal weight loss adversely influenced growth in girls of thin 
mothers. This sex-specific finding was surprising, as boys are generally thought to be more 
susceptible to nutritional insults in utero and postpartum.59 Previously sex differences in milk 
production have been observed in rhesus macaques, where mothers of sons produced higher 
energy and fat milk, but less milk volume compared to mothers of girls;60 however sex 
differences in milk production have not been reported in humans. Given that mothers of boys 
lost marginally more weight than mothers of girls, perhaps mothers of boys were better able 
to mobilize their nutrient stores into milk production compared to mothers of girls. We are 
unable to test this, as we do not have measurements of milk macronutrient composition. 
These findings suggest that further examination of how maternal weight changes relate to 
breastmilk production and infant growth are warranted, especially to understand the sex 
differences we observed.  
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Maternal hemoglobin and transferrin receptors are associated with infant values 
during exclusive breastfeeding 
 
  We aimed to understand how maternal hemoglobin (Hb) and iron status [ferritin and 
transferrin receptors (TfR)] related to infant Hb longitudinally throughout exclusive 
breastfeeding. In a larger sample of BAN mother-infant pairs we used longitudinal regression 
models to relate maternal Hb to concurrently measured infant Hb, after controlling for 
covariates including infant birthweight, rate of weight gain, gender, and infant Hb at birth. 
We modeled infant age with a spline at nine weeks of age in order to capture the non-linear 
trend of infant Hb over time. We tested and observed significant age interactions with 
maternal Hb as well as the covariates rate of weight gain and infant Hb at birth.  
 We found that maternal Hb predicted infant Hb between 6 and 18 weeks postpartum, 
providing further evidence of the strong influence of maternal Hb on infant Hb over time. To 
provide contextual background for our primary analysis, we also examined for associations 
between the BAN study interventions and maternal and infant Hb over time. Though, we 
observed that LNS had no main effects on maternal Hb over time, the ARVs had negative but 
not sustained effects on maternal Hb over time. We observed no intervention effects on 
infant Hb over time, which has been shown elsewhere.79  
 In a subsample of BAN mother-infant pairs, the MaMi subsample, we aimed to 
evaluate how maternal iron status (TfR and ferritin) and Hb related to infant values during 
exclusive breastfeeding after accounting for infection and inflammation using multiple iron 
status indicators. Ferritin and TfR in particular allow for estimates of iron stores and tissue 
iron depletion, reppectively. We used linear regression models to relate change in maternal 
Hb and iron status from initial measurement to 24 weeks to change in infant value, 
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controlling for initial maternal and infant value, infant birthweight, infant gender and whether 
the measurement was obtained at 2 or 6 weeks postpartum.  
 We found that changes in maternal Hb and TfR were associated with change in infant 
value, but found no association between maternal and infant ferritin from initial measurement 
to 24 weeks. The relationship we observed with maternal and infant Hb, further supports the 
findings we observed earlier in the larger BAN sample. Though we observed no association 
between maternal and infant ferritin, we observed that maternal and infant TfR were related, 
suggesting that mothers with depleted iron stores, which manifest as increased TfR levels, 
may have impaired breastmilk iron levels which may adversely affect infant iron status. 
Finally, we evaluated whether adjusting for inflammation and infection in our mother-infant 
iron status and Hb models affects our findings in a sensitivity analysis and observed no 
marked differences in effects. Together these findings in a large sample of BAN infants and 
the MaMi subsample provide evidence that maternal iron status may influence infant iron 
status postpartum independent of the maternal influence on infant’s iron endowment at birth.   
Limitations and Strengths 
  There are several limitations to this study. First, there was much potential for 
selection bias, especially for the analyses with the MaMi subsample. In addition, the study 
requirements for participation were quite rigorous, including many long study visits, many 
questionnaires, blood draws and study demands; hence there was attrition. In addition, we 
excluded HIV-infected infants from analyses due to differences in growth and nutrient 
dynamics during this time. We also excluded infants after cessation of exclusive 
breastfeeding, as the mother was no longer the sole soure of nutrition for her growing infant 
at that time. For example, there were 2,363 HIV uninfected infants at birth with weight and 
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length data, and the sample decreased to 1,754 by 24 weeks postpartum. As such we assessed 
for selection bias in all of our analyses. Generally, we found that mothers and infants 
included in the analyses were healthier than randomized mother-infant pairs, which may have 
been due to excluding HIV-infected and weaned infants. Second, our results may not be 
generalizable to HIV infected infants or HIV unexposed infants. Based on previous research, 
we suspect our growth results will be generalizable to HIV unexposed infants;25 however, we 
do not have a comparison group of HIV unexposed infants. Additionally, our sample of 
mothers and infants was quite healthy relative to other Malawians, and as such our findings 
may not be generalizable to other HIV exposed infants who did not have the consistent 
follow-up and health-care provided by BAN.  
  Another important consideration is whether mothers were truly exclusively 
breastfeeding. Because the BAN study counseled women to exclusively breastfeed for 6 
months, the social desirability bias may have provoked women to report that they were still 
exclusively breastfeeding, when in fact they had introduced complementary foods. If infants 
were receiving other foods, the mother is no longer the sole supplier of nutrition to her infant; 
hence maternal supply will no longer be exclusively related to infant demand, and our 
findings may be biased. We conducted a sensitivity analysis to determine if including weaned 
infants changed our findings. For the weight change analysis, we included weaned infants 
and observed marked differences in primary associations between maternal weight loss and 
infant growth. For the Hb analysis, we included 378 more mother-infant Hb observations and 
observed that the marginally stronger primary effects of maternal Hb on infant Hb.  
 With the success of programs focused on preventing mother-to-child transmission of 
HIV, HIV-exposed-uninfected (HIV-EU) infants are a growing population that may be at 
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increased risk of morbidity and mortality compared to HIV unexposed infants. This study 
took a novel approach to determine the relationships of maternal and infant nutritional status 
during exclusive breastfeeding in HIV-EU infants. We believe this is the first study to 
examine infant iron status longitudinally during exclusive breastfeeding, accounting for 
maternal iron status.  
   This research provides evidence that maternal nutritional status is important during 
exclusive breastfeeding. Our findings regarding early growth of HIV-EU infants, in 
particular, may be generalizable to HIV unexposed infants, as there is little evidence that the 
growth of HIV-EU differs from HIV unexposed infants.25 Ultimately, our findings provide 
guidance for designing interventions to optimize both maternal and infant nutritional status 
and health during pregnancy and lactation.  
Significance and public health impact 
  This study applies a novel framework to explore the dynamic interrelationships 
between maternal and infant nutritional status during exclusive breastfeeding in Malawian 
mother-infant dyads. This study in particular adds to our understanding of growth and iron 
status dynamics of HIV-EU infants, an understudied population. Even though this research is 
in the context of HIV, our methods and findings may be applicable to non-infected 
populations.  
  There is limited understanding of how maternal weight changes shape infant growth 
during lactation. We utilized an innovative modeling approach to explore the complex 
relationships of maternal weight changes and how they affect infant growth, providing 
evidence of feedback loops between the mother and infant, to be examined in future research, 
and also highlighting significant gender differences. The current literature suggests that 
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maternal iron status is not an important determinant of infant iron status during exclusive 
breastfeeding; our study provides evidence that this is not the case and offers much insight 
into mother-infant iron status dynamics during this time. This is one of the first studies to 
examine infant iron status and Hb throughout exclusive breastfeeding, accounting for 
concurrently measured maternal iron status and other important determinants of infant iron 
status. We observed that maternal Hb and TfR are associated with infant values, providing 
evidence that maternal iron status does, in fact, influence breastmilk iron levels and 
potentially infant status.  
  The WHO HIV and infant feeding guidelines were recently updated and recommend 
exclusive breastfeeding for six months, followed by continued breastfeeding to 12 months 
along with provision of antiretroviral medications to the mother or the infant.45,84 These new 
recommendations pose additional demands on maternal nutritional status in addition to 
elevated energy needs resulting from HIV infection. Given these recommendations and our 
findings, it is important to monitor maternal nutritional status during this time in order to 
ensure optimal maternal health so that she may produce optimal breastmilk for her growing 
infant. 
 In summary, this research provides evidence that maternal nutritional status is an 
important determinant of infant status during exclusive breastfeeding.  These findings 
highlight that intervention targeting should focus on not only the infant, but the mother as 
well.   
Direction for future research 
  The BAN and MaMi studies provided us with a novel unique opportunity to examine 
how maternal and infant nutrition were interrelated and interdependent during exclusive 
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breastfeeding in the context of HIV. In our study, we observed that maternal weight loss is 
associated with reduced weight and length gain in girls. Building on this research, future 
studies to examine the complexities of the feedback loops between mothers and infants are 
warranted. Moreover, further research to understand the sex differences we observed. One 
such study could include measurement of energy and protein content of breastmilk in 
mothers of boys and girls to determine if the differences observed in rhesus macaques also 
occur in humans.60 We also observed that maternal Hb and TfR were associated with infant 
values during exclusive breastfeeding. Further analyses of these relationships are needed, 
especially to include additional measures of iron status markers such as zinc protoporphyrin, 
as well as examining different methods to adjust and account for inflammation. Future 
research should also include longitudinal assessment of breastmilk iron content in order to 
understand if changes in maternal iron status influence breastmilk iron content, and then 
subsequently influence infant iron status.  
  Further research applying a mother-infant dyad approach is urgently needed and 
methodological approaches to understand these relationships need to be developed.  For us to 
be able to thoroughly understand these relationships, methods that allow us to understand 
how separate and shared influences of maternal and infant nutritional status affect these 
relationships and methods that allow for incorporation of feedback loops are essential.    
  Given the importance of maternal nutrition we observed, future research should be 
conducted in HIV infected and uninfected populations in both resource rich and resource 
poor settings to further understand these relationships and to determine whether there are 
differences depending on disease status as well as setting. Incorporation of maternal diet as 
well as maternal and infant morbidity into analyses would is also desirable, as these factors 
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may influence the associations we observed. Finally, including measures of maternal 
nutritional status during pregnancy may provide further insight into these complex 
relationships.   
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